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Vascular tissue engineering (VTE) is an emerging alternative therapeutic intervention 
strategy to treat diseases such as atherosclerosis. While the ultimate goal of VTE is 
designing tissues to serve as graft substitutes, they can also serve as powerful tools to study 
tissue and disease development and drug discovery.  
In this work, engineered vascular tissues from fibrin gel, mouse embryonic multipotent 
progenitor cell line (10T1/2 cells), and rat embryonic thoracic artery smooth muscle cells 
(A-10 cells) were used as models to study the Notch signaling pathway and vascular 
calcification. The 10T1/2 cells were successfully differentiated into vascular smooth 
muscle cells with TGFβ1 treatment and compacted the tubular gel significantly owing to 
the contractile cytoskeletal stress fibers. Notch signaling studies in engineered vascular 
tissues from A-10 cells demonstrated cis-inhibition while 10T1/2 cells activated Notch and 
its downstream targets Hes-1 and the smooth muscle α-actin genes.  
The results from the calcification studies showed that vascular tissues fabricated from both 
progenitor and differentiated 10T1/2 cells calcified in response to high inorganic phosphate 
concentrations and expressed the osteopontin protein. Treatment of the tissues with a model 
therapeutic agent, Vitamin K, led to the reduction of calcium deposits and osteopontin 
expression, suggesting its potential protective role. In addition, vitamin K treated 
engineered tissues resulted in the restoration of smooth muscle cells contractile markers. 
The effect of elastin degradation on calcification was simulated using exogenous elastin 
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and showed that while elastin alone did not impact the undifferentiated tissues, it led to an 
increase in osteogenic markers in the differentiated counterparts. 
This work also investigated the role of endothelial cell vimentin in the regulation of Notch 
signaling and neovascularization in coculture tissue models. The preliminary results 
showed that vimentin might enhance the Notch signaling strength since the inhibition of 
vimentin using a chemical inhibitor or siRNA did not completely inhibit the signal. 
Notwithstanding this, vimentin appeared to be essential for new micro-vasculature 
formation.  
The data collectively presented in this thesis demonstrated the potential of engineered 
vascular tissues as a novel tool to study cell signaling, vascular calcification, and 
therapeutic discovery. 
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Summary for Lay Audience 
The lack of organ donors has brought about the need for engineering tissues from the lab 
bench. Whether patients require a blood vessel, bone, a patch of skin, liver, or even a heart, 
tissue engineering provides a practical alternative to the lack of donated tissues and organs. 
This research focused on engineering vascular tissues (blood vessels).  While the main 
purpose of tissue engineering is to replace damaged or diseased organs, the use of 
engineered vascular tissues to study cell communication and diseases that affect the human 
vasculature is a target application. The clotting protein fibrinogen, which is naturally found 
in the blood of mammals, was used to entrap precursor cells and to form a tube-shaped 
tissue that resembles blood vessels. 
Communication between cells is called signaling, and it is a defined “dialogue” that carries 
instructions from one cell to another in a process called signaling pathway. In vascular 
tissues, a vital Notch signaling occurs between endothelial cells and smooth muscle cells 
and dictates vital functions such as cell division and survival, among other functions. In 
this research, the Notch signaling was studied by comparing two different cell types 
responses to endothelial cells in the engineered tissues. It was found that while one type of 
cell was responsive, the other type was not. This has implications for the use of certain cell 
types that are capable of communicating the proper signal for the proper development of 
engineered tissues. Furthermore, by using the engineered tissues as models, a common 
problem that occurs in arteries, vascular calcification was studied. The results in this work 
showed that engineered tissues were capable of calcification just like natural tissues and 
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that there is a potential of using vitamin K to reduce the negative effects of calcification. 
This will help us study diseases and discover treatments for vascular diseases. 
In conclusion, engineered vascular tissues have the potential to provide insight into human 
vasculature physiology and pathology. In this research, it has been shown that engineered 
vascular tissues provide excellent platforms to study cell signaling, vascular diseases, and 
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The role of the vasculature may be seen as a delivery system for blood to transport nutrients, 
oxygen, waste, and carbon dioxide to and from various tissues and organs. However, the 
mechanism and regulation of the processes that govern this seemingly simple task are 
everything but simple. Certainly, regulation of the vascular system to stay in homeostasis 
is critical, and deviation from homeostasis might lead to cardiovascular diseases that can 
be detrimental to the individuals’ health and quality of life. The vast majority of health-
related mortalities can be attributed or linked to cardiovascular diseases, which is a burden 
not only to the patients but also to the economy 1, 2. While cardiovascular disease mainly 
occurs in the elderly population, younger generation cases have been rising due to poor 
dietary and lifestyle choices3. Cardiovascular diseases include atherosclerosis, thrombosis 
and embolism, peripheral artery disease, stenosis, coronary artery disease, aneurysms, etc. 
However, the most common is coronary artery disease triggered by atherosclerosis which 
is the narrowing of arteries due to accumulation of plaque (usually due to fatty streaks) in 
the lumen 4. This leads to reduced blood supply to the heart muscles and eventually heart 
failure.  
At early stages of coronary artery disease patients are prescribed medicine, such as lipid 
regulators like statins, to slow down the progression of the disease. In more advanced stages 
where a plaque occludes the flow of blood to the heart, surgical intervention might be 
necessary. Angioplasty and stenting is a common procedure both to reopen and to prevent 
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the artery from collapsing 5. However, if there are multiple occlusions, then a coronary 
artery bypass graft (CABG) surgery is needed5. This procedure entails using a graft, usually 
autologous saphenous vein, or the mammary artery, to flank the blockages establish 
circulation. While autografts are the safest choices, they are not always available. Allografts 
and xenografts are other options, but usually, they are avoided due to reasons such as 
disease transmission and immune rejection.  
Research in the field of vascular tissue engineering has been ongoing to provide a reliable 
source of grafts that can replace the diseased native tissues. However, despite many 
promising studies, engineered vascular tissues are still not sufficiently developed to be used 
as graft replacement. One of the main challenges is elastin production and crosslinking 
which is a process still scarcely understood. Furthermore, the hierarchical organization of 
cells and their arrangement in the tissue is still hard to control due to poorly understood cell 
processes and signaling pathways. For these reasons, a recent trend in tissue engineering 
has been to use engineered tissues to understand cellular processes in a more relevant three-
dimensional (3D) environment. While much of our knowledge stems from two-
dimensional (2D) cell studies, these studies suffer from many limitations. One obvious 
limitation is that cells do not exist as a monolayer on a plastic surface but in a complex 3D 
milieu that involve interactions with multiple extracellular matrix proteins, different cell 
types, and exposure to dynamic forces that dictate much of the cellular physiological 
processes. As an example, and in the framework of vascular engineering, the vascular 
system is the only system that is continuously exposed to cyclic and variable hemodynamic 
forces. These forces are essential for the proper development and homeostatic maintenance 
of this unique system 6. Indeed, studies have shown that cells in a 3D environment will 
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behave differently when compared to the same cells seeded on a 2D surface7, 8, and that 
forces play an important role in tissue development (reviewed in ref 9). 
While the main objective of engineered vascular tissues is to be used as grafts, they have 
also been used as powerful tools to understand a variety of vascular diseases such as 
atherosclerosis10 and calcification 11. Even though animal and cell models have been 
extensively used to understand vascular pathology, they each have their shortcomings. in 
2D cell culture, the extracellular matrix and other spatial cues are missing. Animal studies 
are complicated by the interference of other organ systems and are usually costly and time-
consuming due to the maintenance of the animals. Furthermore, ethical approvals have to 
be obtained for such studies. This makes utilizing engineered tissues as tools to study 
vascular pathology an appealing idea because they can overcome those limitations. That is 
not to say that animal models will be replaced by engineered tissues. After all, when the 
systematic effect of a disease is to be studied, engineered vascular tissues will not be 
sufficient. However, engineered tissue disease models act as a viable complement which 
narrows down the target of the study and reduces animal studies to focus on a specific 
objective. 
1.2 Thesis outline 
The main objective of this research is to showcase the use of engineered vascular tissues as 
platforms to study cell signaling and calcification. This thesis is composed of 6 chapters as 
follows: An overview of this work is given in this chapter designated as Chapter 1. A 
synopsis of the literature that is relevant to this work is presented in Chapter 2. A study of 
the Notch signaling in engineered tissues follows in Chapter 312. Chapter 4 presented the 
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use of engineered vascular tissues as a model to study calcification13. In Chapter 5, an 
exploratory study of the role of vimentin in regulating the Notch signaling and 
neovascularization is presented. And finally, Chapter 6 summarizes the significance and 
limitations of this research and suggests recommendations. 
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Overview. This chapter provides background information on the vascular system, vascular 
tissue engineering, and the current status of the field. Furthermore, cell signaling is 
discussed with emphasis on the Notch signaling pathway and its relevance to vascular 
tissue formation and development.  At the end of the chapter, an outline of the scope of this 
work and the objectives is provided.     
2.1 The vascular system 
In order to discuss vascular tissue engineering, knowledge about the structure and function 
of the vascular system is essential. Here the important elements of the anatomy, physiology 
and pathology of the different components of the mammalian vascular tissues is 
summarized. 
2.1.1 The anatomy of the vascular system 
The human vascular system is an integral part of the circulatory system which includes the 
heart, the vascular system, and the lymphatic system. These vessels are the arteries, 
arterioles, capillaries, venioles, and veins. With some exceptions (e.g., pulmonary artery), 
arteries transport oxygenated blood, while the veins transport oxygen-poor blood. While 
there are differences between these blood vessels, such as their size difference and the 
presence or absence of valves between veins and arteries, respectively, blood vessels share 
common anatomical elements. Starting from the lumen and moving outward, blood vessels 
are composed of the intima, media, and adventitia1 (Fig 2.1). The intima is composed of a 
single uninterrupted monolayer of squamous endothelial cells. Under physiological 
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conditions, these cells are oriented parallel to the flow of blood. The medial layer is a 
muscular layer that is composed of smooth muscle cells (SMCs) and an extracellular matrix 
(ECM) mainly of elastin and collagen types I and III, but also small amounts of other 
proteins and proteoglycans1. The SMCs and elastic fibers are normally aligned 
concentrically with respect to the central axis of the artery, while the collagen fibers run 
parallel and circumferential to it. In the adventitia, fibroblasts are the abundant type of cells, 
and collagen is the abundant ECM protein. There is no particular alignment of the cells or 
collagen fibers in the adventitia (Fig. 2.1). 
 It is important to note that while these layers are common between arteries and veins there 
are also variations along with the branching of arteries and veins. For example, there are 
notable differences between the thickness and composition of the media of arteries 
depending on the anatomical location. On that basis, arteries are further divided into elastic 
and muscular arteries. Whereas elastic arteries comprise a large amount of ECM and SMCs, 
muscular arteries contain much less ECM and are typically smaller than elastic arteries. 






Figure 2.1. Schematic representation of blood vessel cross-section and its different layers. 
 
2.1.2 Physiology of the blood vessels 
The heart is the blood pumping station for the body, which makes the blood vessels the 
pipes. While this might seem a simple task for an organ system, it is a complicated process 
given the nature of blood as the only fluid tissue and the fact that the body is not always at 
steady-state and is affected by many external and internal factors such as physical activity, 
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stress, disease and others. Hence, the anatomy of the vasculature is explained in part by the 
task to be performed. Starting with the endothelium, it provides a smooth surface layer so 
the blood can pass through with minimal friction. The blood is a non-Newtonian fluid 
which is affected by the level of shear stress it is exposed to, and thus it is critical that blood 
flow is laminar since the turbulent flow has been shown to cause complications, which lead 
to cardiovascular diseases. It also provides a non-thrombogenic surface to keep in mind for 
vascular tissue engineering. This was a common cause of failure of the earlier engineered 
vascular tissues (EVTs). Furthermore, the endothelium acts as a barrier which controls the 
passage of certain molecules to and from the blood stream (blood brain barrier for 
example)1, 2. The endothelial cells also signal SMCs to contract or relax to control blood 
flow using soluble factors such as endothelin and nitric oxide. The media which contains 
the SMCs and ECM proteins has two main functions. The first is to absorb the energy from 
systolic blood and resisting the burst pressure and then returns the energy to the blood to 
keep it moving during the diastolic cycle to keep the blood moving even when the heart is 
resting2. This task is collectively performed by the ECM proteins where collagen mainly 
takes the support function, preventing bursting of the vessel, and elastin is the protein that 
provides elasticity and recoil. The second function of the media is to control the blood flow. 
This is done by the SMCs that are sensitive to vasoconstrictors and vasodilators2. At certain 
locations, the media also contains nerve endings, further regulating SMCs by the 
sympathetic and parasympathetic nervous systems via neurotransmitters1. Arteries usually 
have thicker media than veins because they are exposed to higher pressures. The further 
division of arteries into elastic and muscular is due to their proximity from the heart. Elastic 
arteries are usually closer to the heart, where the pressure is highest, and the muscular 
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arteries are found closer to organs where they regulate the flow of blood. Finally, the 
adventitia plays mostly a structural support function and attaches the blood vessels to the 
surrounding tissues. In larger vessels the adventitia contains blood vessels, called the vasa 
vasorum, and nerve endings.  
2.1.3 Pathology 
The vascular system is subjected to multiple levels of regulations that keep it in check; 
however, under certain conditions, the vascular system may deviate from physiological 
function, which may lead to cardiovascular diseases (CVD). Statistics show that CVDs are 
the primary cause of death worldwide, claiming nearly 18 million people each year3. 
Diseases affecting the vascular system are among the top causes of death in Canada and 
other developed nations. In the United States, almost half the population will be expected 
to suffer from a form of CVD by the year 20354. CVDs primarily target adults and the 
elderly; however, in recent years, more cases of CVDs are occurring in younger adults due 
to the increased prevalence of obesity and poor dietary choices5-7, and reduced physical 
activities6, 8. Furthermore, it can also affect the pediatric population in the form of 
congenital defects.  
Diseases affecting the vascular system are usually caused when one or more of the functions 
of the three layers mentioned earlier are affected. Coronary heart disease (CHD), which is 
the most prevalent form of cardiovascular diseases, is triggered by a plaque that builds up 
in the coronary arteries causing a blockage of the blood flow followed by failure of the 
heart muscles. Plaque buildup in the coronary artery is caused by many reasons, including, 
but not limited to, lipid deposition, a defect in the endothelium or calcification of the intima 
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or the media. In the early stages of a coronary artery blockage, angioplasty is performed, 
and a permanent stent is often placed 'to keep the artery from collapsing. However, in 
advanced stages, where a large section of the artery is blocked or multiple blockages, a 
coronary artery bypass graft (CABG) is required. These strategies have greatly helped in 
reducing the burden of CHD on the lives of many patients, although they are far from the 
ideal treatment. Stenting often causes chronic inflammatory response, which has the 
potential to cause restenosis, eventually requiring a follow-up surgical intervention. 
Moreover, one of the most common shortcomings of CABG is the sourcing of the graft. 
There are three general categories for graft sources: xenografts, allografts, and autografts. 
Xenografts are usually used as a last resort since their use will require administrating life-
long immunosuppressants', and there is a chance of disease transmission that is amplified 
by the immunosuppressants.  
The gold standards for autografts are the saphenous vein and the mammary artery having a 
similar diameter to the coronary artery, and they are accessible with minimal surgical 
intervention. One of the problems with using those grafts is compliance mismatch, which 
is a well-known cause of graft failure9, 10. Due to the difference in mechanical properties 
and because of the inherent pressure differences that these blood vessels are exposed to in 
their native settings, compliance mismatch is usually an issue that leads to turbulent flow 
at the anastomoses site and causes thrombosis, hyperplasia and low patency11. The age of 
patients and/or their overall health status are also constraints that might hinder the use of 
autografts. Neointimal hyperplasia is a problem in both angioplasty and CABG, which is 
caused by the damage these procedures inflict on the endothelial cell (EC) lining of the 
vasculature. In angioplasty, the catheter inserted into the artery and inflating the balloon 
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will lead to sloughing off the ECs. This is an issue since the regulation of smooth muscle 
cells (SMCs) proliferation by ECs has been well documented in the literature12-15. There is 
increasing evidence that the Notch signaling pathway plays an important role in that 
process. The Mequanint Lab and others have documented the importance of ECs interaction 
with SMCs via the Notch pathway and the effect it has on regulating SMC gene 
production13, 14, 16, and consequently inhibiting smooth muscle cell phenotypic switching to 
a proliferative state. Therefore, there is a need to find an alternative to these treatment 
modalities that would overcome the shortcomings of current grafts. The work in this thesis 
proposes that targeting the Notch signaling pathway is a pivotal step not only to help control 
the phenotypic switching of SMC, but also to fabricate fibrin-based vascular constructs that 
closely resemble small diameter arteries for applications like preclinical test models or as 
graft replacements. Furthermore, this might enable the development of strategies to 
overcome the shortcomings of angioplasty for example, by modifying stent surfaces. 
Vascular calcification is another common disease that not only affects the coronary artery, 
but also in other parts of the vascular system and is especially prevalent in patients with 
renal dysfunction. Calcification in the vascular tissues is caused by multiple factors such as 
cell apoptosis/necrosis, calcium/phosphate ions imbalance (renal dysfunction), bone  
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degeneration, degradation of the ECM proteins, and inflammation. Calcification will be 
discussed further in later sections. In summary, whether the problem is finding replacement 
vascular grafts, studying disease or understanding signaling pathways, vascular tissue 





2.2 Vascular tissue engineering 
Tissue engineering has emerged as a subdivision of a broader field of regenerative 
medicine. It is a multidisciplinary field of research that includes material science and 
engineering, biology and biochemistry for the purpose of generating bioartificial tissues. 
Figure 2.2. Graphical abstract of section 2.2. Schematic representation of the basics of 
vascular tissue engineering and their use as disease models 
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Research in tissue engineering was initiated as a viable solution to the shortage of organ 
donations. There are many promising studies that have demonstrated the feasibility of 
fabricating tissues such as bone17-19, skin20, 21, blood vessels22-24, and others25, 26 to produce 
functional tissues that will treat or replace diseased or injured organs. Vascular tissue 
engineering is an active field of research producing a vast number of studies at a fast pace. 
Therefore, it is important to mention some distinct milestone studies that have shaped this 
field into its current state.  
2.2.1 Important milestones in vascular tissue engineering  
Vascular tissue engineering started in 1986 when Weinberg and Bell made a small diameter 
vascular tissue-equivalent out of collagen and bovine cells27. While this was a promising 
attempt at engineering a vascular graft, the Dacron sleeve was needed to support it, and this 
limited its success due to its inert vasoactivity. Thus, there were attempts to strengthen 
collagen, as a natural polymer, to withstand hemodynamic pressures. In a different study, 
Wilson et al. developed a protocol to decellularized arteries using detergents and enzymes, 
creating a cell-free matrix that preserved the structural integrity of those arteries while 
allowing the host cells to infiltrate and populate the scaffold28. A different approach to 
engineer vascular tissue was employed by L'Heureux et al. using confluent cells to produce 
their own ECM forming tissue sheets and then rolling them on a mandrel to make a tubular 
tissue resembling a blood vessel29. While these tissues had promising mechanical 
properties, the culture period to obtain such tissue sheets was considerably long. Niklason 
et al. made vascular tissues using polyglycolic acid as a scaffolding material and were 
transplanted into a bovine animal model where they stayed patent for 24 days30. This study 
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highlighted the importance of the use of synthetic materials; however, it also brought into 
light a critical disadvantage represented by harmful degradation byproducts. While research 
groups used in vitro culture systems to mature their EVTs, an interesting idea that suggested 
an in vivo culture system was introduced31. The presented idea was to insert the bare 
scaffold into an animal model, and the animal itself provides the resident cells, the right 
environment, and growth factors. On the materials front, the main natural polymer used in 
vascular tissue engineering was collagen. This is because collagen is one of the main 
components of vascular tissues. However, several studies reported the use of fibrin as 
another viable scaffold for EVTs, because it is easily available from a patient's blood32. 
These studies laid the foundation of vascular tissue engineering and are the basis for our 
current understanding. 
The focus of this thesis work is the arteries, and in particular the small diameter coronary 
and peripheral arteries. Previously the relationship between the anatomy and the physiology 
of blood vessels it was mentioned.  To match the functional and biological roles of the 
native artery, the engineered counterparts must exhibit similar features. In small diameter 
arteries such as the coronary artery, the two functional layers are the intima and the media. 
The average wall thickness is around 1.1 mm, a luminal diameter of about 2.2 mm and an 
external diameter of 4.5 mm33.  
The intima is a single layer of endothelial cells which can be achieved by seeding the lumen 
of the engineered vessel with a high-density endothelial cell suspension. On the other hand, 
the media comprises multiple layers of smooth muscle cells and ECM proteins and has an 
average thickness of 200 µm34.  Different research groups have devised various techniques 
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and materials and have used cells from different sources to fabricate engineered vascular 
tissues with a varying degree of success 23, 30, 35-37. The two main components of EVTs are 
the material to be used as a scaffold to hold the cells and the cells themselves. There have 
been different materials used as scaffolds for vascular tissues, which are divided into two 
main categories: synthetic or natural polymers. Moreover, there are many cell types that 
can be potentially used in vascular tissue engineering, and they are also divided into two 
general categories: differentiated (non-stem) cells, namely endothelial cells and smooth 
muscle cells, and stem cells, which can be differentiated via soluble factors, mechanical 
stimulations, etc. into the desired type of cells. These will be discussed in more detail in 
the following sections. 
2.2.2 Cell types and sources used for vascular tissue engineering 
In the context of vascular tissue engineering, cells are responsible for the major 
functionality of the tissues. After all, endothelial cells constitute the anti-thrombogenic 
surface, and SMCs produce the ECM and regulate the diameter of blood vessels, among 
other functions. Thus, the sources of cells to be used to engineer the vascular tissue must 
be chosen with intent, and for that reason, the cell sources for vascular tissue engineering 
have been a cause of extensive debate38, 39.  
The first logical cell source is native primary endothelial and SMCs as they are the 
functional cells of the vasculature and are available from a biopsy. However, the use of 
primary cells has proven to be challenging because of their limited proliferation rate, which 
depends on multiple factors, the most important of which is the donor age and health 
status40, 41. Thus, stem cells have been suggested as an alternative due to their proliferative 
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potential. Sources of stem cells include adult stem cells (e.g. mesenchymal stem cells and 
adipose tissue-derived stem cells), embryonic stem cells, and induced pluripotent stem 
cells. Using stem cells has shown potential in vascular tissue engineering not only due to 
their high proliferation capabilities but also the capacity to be differentiated into both ECs42-
44 and SMCs44, 45. Stem cells have been extensively studied due to their multipotency; 
however, this property of stem cells seems to be a doubled-edged sword. The fact that these 
cells can be differentiated into many lineages makes it difficult to control the desired cell 
lineage for a specific tissue, often leading to a mixed population with other undesired 
types46. The fact remains that there are many variables that have to be controlled in order 
to successfully differentiated stem cells to functional SMCs and/or ECs. Furthermore, stem 
cells in adult individuals are scarce in comparison to differentiated primary cells, and the 
procedure of getting certain stem cells, such as bone marrow stem cells, is invasive and 
painful. Indeed, more research is needed to understand the differentiation pathways that 
will lead to the specific cell lineage and therefore produce functional engineered vascular 
tissues. 
2.2.3 Vascular tissue engineering strategies 
Many strategies have been implemented in vascular tissue engineering to ensure structural 
and cellular organization and mechanical integrity that resemble those of native human 
blood vessels. As mentioned in previous sections, blood vessels possess important 
structural and cellular organizations (such as the concentric organization of the layers of 
SMCs, the longitudinal assembly of collagen fibers, the centripetal formation of elastic 
fibers, etc.) that impart crucial physiological functions such as the antithrombotic lumen 
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and the vasoactivity of the medial layer. These purposeful and organized structural 
elements have been among the most challenging aspects of tissue engineering in general 
but especially in vascular tissue engineering. This is due to the sensitive function of each 
of those cellular and structural components because of the exposure of these constructs to 
a continual dynamic environment carried out by the systolic and diastolic cycles of the 
circulatory system. Therefore, there has been a great effort to develop various strategies 
and methods to give engineered tissues the structural and functional properties of their 
native counterparts. 
2.2.3.1 Cell sheet- based EVTs 
This is one of the earliest methods used in the fabrication of engineered vascular tissues. It 
was developed by L'Heureux et al. in 199829 where vascular tissues are formed by growing 
high-density monolayers of smooth muscle cells that are coaxed to produce extracellular 
matrix proteins by treatment with ascorbic acid. After a period of time in culture, the cells 
form a cohesive sheet that can be removed and rolled into a cylindrical mandrel to form the 
signature tubular structure of vascular tissues. Even though the EVTs formed using this 
method usually exhibit favorable mechanical properties and have even been grafted in a 
canine model, their production time is exceedingly long, topping three months of culturing 
and maturation periods. These prolonged periods of culturing and maturing will inherently 
increase risks of contamination and will also prevent the use of these tissues as ready-made 
off-the-shelf constructs. The main reasons for this prolonged period to fabricate such tissues 
is due to the slow production of the ECM by SMCs and their slow proliferation rate. 
Therefore, an attempt was made to reduce that time by utilizing skin or saphenous vein 
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fibroblasts47. Fibroblasts are known for their fast production of ECM. After the fibroblast 
cell sheets were produced, the sheets were decellularized, and SMCs were seeded on the 
sheets and wrapped around a mandrel in a similar fashion as that employed by L'Heureux 
and co-workers. These EVTs were comparable to the ones produced by SMCs; however, 
their production time was still relatively long even though they were able to improve the 
maturation period by two weeks47. 
2.2.3.2 Decellularized scaffold-based EVTs 
Production of an organized and well-structured ECM by cultured cells has proven to be a 
long and complicated process that scientists are yet to understand completely. In the context 
of vascular tissues, the ECM plays a critical role in the physiology of the tissues. Therefore, 
it is essential to replicate the fibrillar organization and content of the different layers of the 
blood vessels to produce a functional tissue. The ECM of a typical artery is composed 
mainly of collagen and elastin with other less abundant proteins and glycosaminoglycans. 
Collagen is relatively easily produced by SMCs and fibroblasts by treatment with ascorbic 
acid. Elastin fiber production, on the other hand, has been elusive and has proven to be a 
challenging task in vascular tissue engineering that might require not only soluble factors 
but also mechanical stimulation of the tissues48. While the production of these ECM 
proteins is essential, the organization of their fibers is equally important. It is not enough 
to have random fiber arrangement in vascular tissues; they have to be aligned properly for 
the EVTs to have meaningful structural integrity. Hence, researchers have resorted to 
taking advantage of already existing blood vessels to circumvent this particular problem. 
This method involves obtaining a blood vessel either from the same individual that requires 
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the graft (autologous graft), from a different individual (allogenic graft) or a different 
species (xenogeneic graft) and decellularizing the blood vessel.  After decellularization, the 
scaffold could be utilized as is and allow the host cells to infiltrate it, or cells will be seeded 
onto the preserved ECM scaffold and matured in culture or bioreactor before using it as a 
graft. Both autologous and allogenic grafts exhibit minimal immunogenicity; however, 
xenogeneic grafts might still show a degree of immune reaction by the host.  
The role the extracellular matrix plays in cellular motility49, differentiation50, 51, and 
proliferation52 is well documented in the literature. The advantage of this strategy is that it 
preserves the ECM structure, topology, and even certain growth factors embedded in the 
ECM, all of which have been shown to affect cell function one way or another. 
Traditionally, vascular tissues from a host were used to make decellularized scaffolds; 
however, some groups have used decellularized scaffolds from engineered tissues47, 53. 
Decellularization of tissues is accomplished through different approaches, including 
chemical, biochemical, and physical. Of course, the effectiveness of the approach will 
depend on factors such as tissue composition, dimensions, and cellular density, among 
others. Chemical agents include, but are not limited to, acids/basis54, hypertonic solutions55, 
detergents (ionic and non-ionic)55, 56, some alcohols54, 56, etc. Biochemical reagents are 
enzymes such as nucleases, trypsin or dispase54, 57, and physical decellularization includes 
temperature change51, shear force/pressure 58, and electroporation 59. Each of these agents 
will affect the ECM in one way or another, and thus, oftentimes, a combination of those 
strategies is employed to achieve optimal decellularization while preserving the ECM as 
much as possible 54. 
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Decellularized tissues have shown promising results; however, they still suffer from 
limitations such as thrombosis, infection, inflammation, aneurysm, and poor patency. A 
clinical trial that compared a decellularized bovine ureter against polytetrafluoroethylene 
in arteriovenous vascular access grafts for dialysis patients showed no advantage of the 
decellularized tissue over the synthetic graft 60. Therefore, while the idea of using 
decellularized conduits for vascular tissue engineering is promising, more research is 
required to address the previously mentioned shortcomings. 
2.2.3.3 Scaffold-based EVTs 
Scaffold-based engineered vascular tissues are arguably the most widely used strategy to 
fabricate vascular prostheses. This strategy entails forming a scaffold onto which the 
desired cells will be seeded. The scaffold provides structural support and a suitable 3D 
environment for the cells to deposit their ECM. Ideally, the synthetic scaffold should be 
remodeled and replaced by the resident cells. However, certain materials have been used 
that are not biodegradable and the current state of tissue engineering is focusing more on 
biodegradable materials. As a general guideline, a scaffold should have the following 
properties: a) acceptable surface properties to allow cell adhesion and viability, b) 
sufficient porosity, interconnectivity, and proper pore size permitting cell infiltration as 
well as nutrient and oxygen exchange, c) a degradation rate that matches ECM formation 
by cells, and d) be mechanically competent to withstand the hemodynamic forces. 
Materials including synthetic and natural polymers, which are also subdivided into 





Both biodegradable and non-biodegradable synthetic materials have been explored in 
vascular tissue engineering. However, non-biodegradable materials are being phased out 
due to reasons such as low-grade chronic inflammation, compliance mismatch, and the fact 
that they are permanently present in the patient's body. Although synthetic materials, such 
as polyurethane, Dacron, and Teflon have been successfully used as prosthetics to replace 
blood vessels that are greater than 6mm in diameter61, their use to replace blood vessels 
with diameters of less than 6mm has been met with limited success due to thrombus 
formation62. The advantage of biodegradable materials is that they act as a temporary 
scaffold. The degradation rate can usually be tuned, and thus the cells can degrade the 
material while producing their own ECM until the whole scaffold is replaced by ECM 
produced by the engineered tissues and recipient's body. Biodegradable synthetic polymers 
are sometimes prepared from lactic acid, glycolic acid, caprolactone, or a copolymer made 
of different ratios of these monomers 35, 63-65. Synthetic materials exhibit many advantages 
for their use in vascular tissue engineering, such as: (i) minimal batch-to-batch variations 
which is important for upscaling, (ii) relative ease of functionalization with biomolecules, 
allowing them to have better interaction with cells and host body, and (iii) tailorable 
mechanical properties to withstand hemodynamic forces66. On the other hand, synthetic 
biomaterials usually suffer from poor cell infiltration, the restricted capacity of remodeling 
by cells, foreign degradation byproducts, and limited bioactivity, especially in the absence 





These materials are usually protein-based polymers such as collagen67, 68, elastin69, 70, 
fibrinogen24, 32, 36 or a combination71-73. However, other natural polymers in the form of 
polysaccharides which do not normally biodegrade in humans have also been used, such as 
cellulose74. One of the advantages of using these polymers is that they are native body 
components and are usually found in the cell physiological niche. Thus, cells possess the 
enzymes and surface receptors that will interact with these polymers making remodeling a 
continuous process. Another advantage is the ability to embed cells while crosslinking these 
polymers which is not feasible with synthetic polymers due to the harsh conditions need to 
crosslink them (solvents, UV, etc.).  Furthermore, protein-based polymers contain domains 
that enable cell interaction and impart important physiological responses that guide the 
healing process. On the other hand, while these materials are advantageous on the 
biological side, they usually lack mechanical strength to withstand hemodynamic forces. 
Nevertheless, these polymers have shown promising results as graft substitutes 24, 75. 
Methods of scaffold fabrication 
Ever since the foundation of tissue engineering, there have been a myriad of methods 
developed to fabricate scaffolds which is one of the main building blocks of engineered 
tissues. Methods such as freeze-drying, gas foaming, phase separation, electrospinning, and 
solvent casting-particulate leaching (SC-PL) have all been used, and each has its pros and 
cons. In this section, a brief description is provided on the most commonly used scaffold 
fabrication methods in vascular tissue engineering.  
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Electrospinning: this is a common technique used for the production of nano- and 
microfibers. In this method, a polymer is dissolved in a solvent at an optimized ratio and 
loaded into a syringe placed in a syringe pump. During electrospinning, a high voltage is 
applied to the tip of the syringe while the syringe pump, at a very slow rate, ejects the 
polymer solution forming a droplet at the tip of the syringe due to surface tension. The high 
voltage then counteracts the surface tension of the droplet, causing an eruption of 
electrically charged get of a polymer solution. As the polymer jet shoots towards the 
collector, the solvent evaporates, forming fibers. The structural properties of those fibers 
can be modified by adjusting parameters such as voltage, solvent used and ratio of polymer 
to solvent, the molecular weight of the polymers, syringe pump flow rate, etc. The 
advantage of electrospinning is that it produces fibers similar to those found in the ECM of 
tissues. On the other hand, scaffolds produced by electrospinning are usually difficult to 
penetrate by cells due to low pore interconnectedness.  
Solvent casting-Particulate leaching: SC-PL is a widely used method due to its 
simplicity. This method involves a mold that determines the bulk shape of the scaffold, 
which in vascular tissue engineering is usually an outer cylindrical tube and an inner 
cylindrical mandrel creating an annular space between the two. To fabricate the scaffold, a 
porogen (usually a salt) is packed into mold, followed by the dissolved polymer. Once the 
polymer is cross-linked the mold is disassembled, and the scaffold is placed in a solvent 
that dissolves the porogen resulting in a porous scaffold. The pore-size and shape, which 
are inversely related to the structural strength of the scaffold, can be controlled by varying 
the size and shape of the porogen which helps the interconnectivity of the pores and 
improves surface area leading to better cell growth, infiltration and nutrient/gas exchange. 
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While SC-PL is a simple and relatively fast method, the scaffolds produced by this method 
do not resemble the extracellular matrix environment of vascular tissue. Furthermore, the 
solvents used in this method are toxic to cells, which requires many washing steps to get 
rid of any residual solvent. 
3-Dimensional (3D) printing: with the rapid advancement in computers and 3D printers, 
making scaffolds using computer-designed/3D printed scaffolds has become an 
increasingly appealing application for tissue engineers. This method starts with a 3D design 
using computer software. Then the digital blueprint is sent to a 3D printer that prints the 
scaffold using thermoplastics, for example. This method is solvent-free, which is beneficial 
for cell seeding in downstream applications. A more recent development in 3D printer 
technology has brought about the use of bioprinting. This method utilizes what is known 
as bioinks, which are composed of cells encapsulated in hydrogels. The advantage of this 
method is that it can replicate fine topographical details of native tissues that and 
circumvent issues such as cell infiltration since the cells are part of the printed materials. 
Furthermore, this method has the potential of scaling up for mass production. On the other 
hand, the limitations of this method include cost and resolution of the printed materials.  
2.3 Cell signaling 
It was traditionally believed that cells communicated solely via soluble factors or cell-cell 
interactions; however, emerging evidence has shown that cells can respond to many other 
forms of signals such as magnetic forces, electromagnetic fields, sonic vibrations and 
interactions with surrounding cells and matrix proteins. We have reviewed these atypical 
cell stimulations in the context of stem cell differentiation76; however, other cell types also 
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do respond to unconventional signaling.  In the vascular system, resident cells like the ECs 
and SMCs have been shown to respond to hemodynamic forces such as shear stress77 and 
pulsatile strain78 in addition to the traditional signaling. While there are many signaling 
pathways that are considered essential and are involved in the developing and maintenance 
of blood vessels, Notch signaling is one of the major pathways and is indeed relevant in the 
context of cellular organization and regulation in engineered vascular tissues.  
2.3.1 Notch signaling pathway 
There is a myriad of stimuli that dictate the development of the anatomy and physiology of 
the vasculature. These include chemical, biochemical, and mechanical stimuli that work 
individually or in tandem to guide the development and organization of the cell layers in a 
blood vessel. While the general trend in vascular tissue engineering is to treat tissues with 
bioactive molecules or mechanical stimuli and expect to produce functional tissues, taking 
advantage of cell signaling to instruct cells to produce vascular tissues with desirable 
features is proposed. One of the central signaling pathways that govern the development, 
physiology and pathology of the vasculature is the Notch pathway79. There are four Notch 
receptor variants in mammals, Notch 1 to 4, all of which are type I transmembrane receptors 
and range from ~120 to 280 kDa in molecular weight. All the Notch receptors share similar 
structures and domains. They are single-pass membrane proteins with an extracellular 
domain (N-terminus), a membrane-spanning domain, and an intracellular domain (C-
terminus). Notch receptors interact with five ligands: Delta-like ligand (Dll) 1, 3, 4 and 
Jagged (Jag) 1 and 2. These ligands are transmembrane proteins with structural and domain 
similarities. Canonical Notch signaling occurs when the ligand of the signal sending cell 
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(SSC) interacts with the receptor from the signal receiving cell (SRC) (Fig 2.3 step 1). This 
triggers an enzymatic cleavage of the receptor ectodomain by the enzyme ADAM (A 
Disintegrin And Metalloprotease) (step 2), leading to endocytosis of the ligand and the 
Notch Extracellular domain (NECD) (step 3).  
 
Figure 2.3. Schematic representation of the canonical Notch signal transduction. 
 
This is followed by another enzymatic cleavage by γ-secretase (step 4), which releases the 
Notch intracellular domain (NICD) into the cytoplasm (step 5). Once in the cytoplasm, the 
NICD translocates to the nucleus, where it forms a transcriptional complex with RBP-Jκ 
transcription factor leading to transcription of target genes including Hes, Hey and smooth 
muscle alpha-actin (Acta2) (step 6). On the other hand, non-canonical Notch signaling has 
been reported and involves cross-talk between the Notch receptors with members of other 
signaling pathways like Wnt, MAPK and TGFβ80-82. Furthermore, Notch signaling has also 
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been shown to occur at a distance via cell protrusions83 and filopodia84 which can explain 
the signaling between ECs and SMCs across the internal elastic lamina. In the adult 
vasculature, endothelial cells predominantly express the Notch1 and 4 receptors, while 
SMCs mainly express Notch3 and, to a lesser extent, Notch1 and 285, 86. On the other hand, 
Dll1, Dll4 and Jag1 and 2 are the main ligands expressed on ECs, whereas SMCs express 
Dll1, Jag1, and Jag285, 87. The expression of these ligands and receptors on the surface of 
these cells tend to change with development and disease and even in the different branches 
of the vasculature88. There does not seem to be a particular affinity of one of the receptors 
to any of the ligands, meaning that any receptor is equally capable of interacting with any 
of the ligands. However, not all receptor-ligand contacts produce a signal89. This might 
indicate that these interactions play a role in signal regulation.  
Notch signaling has long been known to be a major regulator and an essential element in 
the homeostasis of the cardiovascular system 88. Animal studies demonstrated that 
dysregulation of the Notch receptors or their ligands has detrimental effects. For example, 
the Dll4 ligand was determined to be essential for the normal development of the 
vasculature since haploinsufficiency in the gene will lead to embryonic lethality resulting 
from defects in the development of arteries90. Conversely, expression of a constitutively 
active form of Notch4 in the endothelium of embryonic mice also shows abnormalities in 
the development of the vasculature and is also embryonic lethal91. Notch3 knock-out in 
adult mice exhibit structural immaturity and are not responsive to vasoconstrictors such as 
angiotensin II or phenylephrine92. In humans, Notch3 mutations cause Cerebral Autosomal 
Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) 
due to increased multimerization of the receptor at the surface of the cell and its subsequent 
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degradation93, 94. These studies point to the importance of the Notch signaling and its 
regulation, warranting the significance of this receptor in the development of the 
vasculature system.  
The expression of the Notch receptors and their ligands vary between the endothelial cells 
and SMCs and even between the same cell type in different branches of the vasculature. 
However, the Notch3 receptor and the Jag1 ligand is more relevant for this thesis since they 
are the major proteins expressed by the SMCs and ECs, respectively85-87. The activation of 
the Notch signaling pathway within the vascular context has been implicated in the 
development and regulation of the SMC phenotype by modulating the expression of certain 
SMC genes14, 16, 95 which is the reason it is the focus of this study. 
2.3.2 Notch regulation 
At first glance, the canonical Notch signaling pathway seems to be a simple, 
straightforward signaling mechanism between the SSC and SRC. Compared to other 
signaling pathways, Notch signaling has no secondary messengers involved and no signal 
amplification. How can a seemingly simple pathway be conserved among many species 
and regulate such vital processes in developing animals from development to adult life? 
The short answer is that it is not a simple pathway. Even though it has been over a century 
since the discovery of Notch, it is still not a well-understood pathway. It is regulated by 
various mechanisms from the moment the receptors and ligands are translated in the 
endoplasmic reticulum to the moment they are degraded/recycled. After Notch is 
synthesized, it is modified by the addition of O-glycans (O-fucose,-glucose,-GlcNAc and -
xylose), which appears to play a role in ligand sensing96. After the interaction with the 
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ligand and the intracellular domain of Notch is cleaved, the NICD translates to the nucleus. 
The NICD itself has been shown to be affected by various post-translational modifications 
to further regulate this pathway. Observations have shown that the NICD can be 
methylated97, acetylated98 and ubiquitinated99. These modifications will modulate the 
extent of activation or inhibition of downstream targets of the notch pathway. While the 
NICD is thought to directly translocate to the nucleus, evidence has shown that Rab5 
regulates an alternate route of NICD transport via endosomes100. This route then forks into 
two different paths, either to the nucleus and signaling activation or to the lysosome and 
signal attenuation. Not surprisingly, these routes are also regulated. PIM (Proto-oncogene 
serine/threonine) kinase has been shown to phosphorylate a sequence of the Notch nuclear 
localization domains enhancing the signal101, while ESCRT proteins control its 
translocation to lysosomes leading to signal attenuation102.  
A defining feature of the Notch signaling is that both the receptor and the ligand are cell-
surface proteins. While the mentioned regulating steps occur at the receptor end of the 
signaling, the ligands are also subjected to complex cellular regulations. For example, 
ligand recycling to the surface of the SSC which ensures continual signaling, is regulated 
by E3 ubiquitin ligases103, 104. Furthermore, the number of ligands on both SSC and SRC 
will dictate whether the signal will be activated or repressed via a mechanism known as 
cis-inhibition105. Studies have shown that whether the cell will behave as an SSC or SRC 
is contingent upon the relative numbers of the receptors and ligands on that cell. If a 
particular cell expresses more ligands than receptors on its surface, it will be an SSC; 
however, if it expresses more receptors than ligands, it is an SRC. Alternatively, if the ratio 
of receptor to ligand approaches 1, then the cell will be neither SSC or SRC and thus will 
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be cis-inhibited105, 106. However, a recent publication has shown that this is not always the 
case as  the interaction of the receptor with the ligand on the same cell might activate the 
signaling transduction via cis-activation 107. This level of regulation at multiple steps of the 
seemingly simple pathway shows the complexity that allows this pathway to regulate many 
vital cellular and developmental processes. Furthermore, the fact that there are many 
conflicting functions of this pathway hints at its dependence on the context in which the 
signaling is occurring. 
2.4 Engineered tissues as disease models 
The advent of tissue engineering has been aimed to fabricate functional tissue substitutes 
to repair or replace damaged tissues or organs. There has been promising progress as 
evidenced by different clinical studies that use various types of engineered tissues65, 108-111. 
However, even with the substantial progression of cell and molecular biology (especially 
cell isolation, differentiation, stemness restoration, etc.); and biomaterial science and 
engineering enabling the preparation of tailor-made scaffolds with tuned molecular and 
chemical properties, only a few engineered tissues that are comparable to the native 
counterparts on structural and functional levels have emerged. If anything, this fact 
emphasizes the challenges to develop functional tissues. The major challenges are the lack 
of knowledge in culture parameters and conditions (especially cell differentiation), delivery 
of biochemical and mechanical stimulations, structural organization of the tissues and 
direction of cellular orientation. Nevertheless, the purpose of engineered tissues has 
expanded to include an equally significant application as in vitro model platforms to study 
diseases and for the development of treatment strategies. Even though preclinical platforms 
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such as cell culture and animal models have contributed significantly to the current 
understanding of pathology and physiology, they have their shortcomings. On the one hand, 
the 2D culture systems exclude the vital biochemical and biomechanical cues of the 
extracellular matrix (ECM), which is known to affect molecular and cellular processes and 
thus might lead to results that may not be relevant physiologically. On the other hand, 
animal models do not reflect genetic, physiological, or anatomical elements of the human 
species and, again, lead to irrelevant results. Not to mention the high cost of maintenance 
and the ethical concerns that accompany animal studies. Conversely, engineered tissues can 
be fabricated using relevant human-derived cells and include or intrinsically produce their 
own ECM components, thereby overcoming the shortcomings of current preclinical 
models. Another important advantage of engineered tissues is the ability to control the 
manufacturing procedure and, consequently, highly reproducible results. Additionally, 
engineered tissues have the advantage of being an isolated system that can be used to 
systematically study disease without the effect of other organs. On the other hand, if the 
impact of one organ/tissue on another has to be established (such as the effect of bone 
resorption on the calcification of vascular tissues), different engineered tissues can still be 
coculture to study that correlation. Of course, this does not totally exclude the use of animal 
studies since there is a certain level of systemic complexity that the engineered tissues lack 
and is important and required before the transition to human trials. 
2.4.1 Engineered vascular tissue disease models and test platforms 
Vascular tissue engineering is a relatively new field of research. The focus of published 
studies revolved around exploring different cell types24, 38, 112, bioreactor parameters and 
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culture settings113, 114, and different materials30, 115 to find the right combination of 
parameters that produce an engineered tissue that best resembles the native vascular tissues 
in both structure and function. That being said, a few numbers of studies have started 
emerging that use engineered vascular tissues as disease models or as platforms to test 
medical devices or treatments. 
Atherosclerosis is a prevalent cardiovascular disease and is one of the major causes of 
morbidity around the world. As such, many of the studies that emerged to model and 
understand cardiovascular disease are aimed at different aspects of the pathophysiology of 
atherosclerosis. For example, one study used an engineered  vascular tissue as an in vitro 
model to study monocyte attachment and insudation as well as LDL insudation into the 
media of the fabricated tissues116. Another similar study but with fibrin gels explored the 
insudation of lipoproteins and monocytes at hypo-, normo- and hyper-cholesterolemia117. 
A follow-up study by the same group utilized the same fibrin gel system to study neutrophil 
granulocyte penetration and production of matrix metalloproteinases of a neointimal 
model118.  
A more recent study modeled a less common disease, the Hutchinson-Gilford Progeria 
Syndrome (HGPS), which is characterized by accelerated aging and loss of functionality in 
the SMC of vascular tissues.  Engineered vascular tissue was made from type-I collagen 
and iPSC-derived SMCs obtained from patients with HGPS119. These tissue models showed 
a lower response to vasoconstrictors and lower expression of SMC contractile proteins 
compared to tissues where the cells were sourced from healthy individuals. Furthermore, 
this study explored a treatment for the HGPS using a rapamycin analog compound and 
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showed that some functionality of the diseased engineered constructs was restored within 
one week of treatment119. 
Vascular calcification is yet another disease that has lately been modeled in vascular tissue 
engineering. In this first of its kind research study, acellular engineered vascular tissues 
were used to study the physical characteristics of vascular calcification and the effect of 
high calcium and phosphate ions in the culture media has on the histochemical, structural, 
thermal and mechanical properties of these models120. However, a major weakness of this 
study was that it did not explore the cellular response to calcification which are active 
contributors to the calcification of vascular tissues. Coincidently, the Mequanint lab was 
working on that specific topic around the same time,  aimed specifically at the role 
progenitor and differentiated cells play during the calcification of engineered vascular 
arteries121 which is discussed in more detail in chapter 4. 
The potential of EVTs extends even beyond modeling diseases and has also encompassed 
developing new medical devices as well as studying the effect of medical devices on 
tissues. Stents are commonly involved in the treatment of coronary artery occlusion due to 
atherosclerosis, and thus, they are a relevant device to test in engineered tissues. A protein-
loaded stent was used to evaluate the behavior of SMCs in the medial layer of engineered 
vascular tissues122. In a different study, a group of researchers employed EVTs to study the 
effect of stent deployment on the endothelial cells in a bioreactor under physiologically 
relevant conditions123.  
These studies emphasize the potential and feasibility of engineered vascular tissues to study 
different aspects of the same phenomenon by systemically introducing different variables 
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at a time. This allows an understanding of the separate elements involved in a process and 
then putting all the elements together to look at the bigger picture. Furthermore, these 
studies show the feasibility of using EVTs as drug and medical device test platforms. 
2.5 Motivation and significance of this work 
This work was inspired after identifying a novel use of engineered vascular tissue as 
templates to study cell signaling and disease modeling. Herein, the focus is on the notch 
signaling pathway which is an essential pathway in vascular development. Furthermore, 
this research presents novel studies that were amongst the first that used engineered 
vascular tissues as a disease model for vascular calcification producing only the second 
study ever to be published on this subject121. 
2.6 Research scope and objectives 
The scope of this research is to showcase the use of engineered vascular tissues as platforms 
to study cell signaling and disease models. As a pivotal signaling pathway that is implicated 
in the development and disease of the vascular system, the Notch signaling pathway was 
chosen for this research. Furthermore, calcification of the vascular tissue has never been 
studied in an engineered tissue model, and thus EVTs were chosen as tools to study the 
development of medial calcification and explore a potential adjuvant treatment for it using 
vitamin K. To lay the grounds for this research scope, the following objectives were 
identified: 
1- Comparison of the response of differentiated vs. progenitor cells in Notch signaling 
activation via a 3D coculture system with endothelial cells (Chapter 3). 
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2- Study the role of progenitor and differentiated cells in engineered vascular tissue 
calcification and the role of vitamin K as a calcification inhibitor (Chapter 4).  
3- Explore the role of vimentin, as a mechanosensory fiber, in the activation of the 
Notch signaling and neovascularization (Chapter 5). 
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Chapter 3 
Comparative studies of fibrin-based engineered vascular 
tissues and Notch signaling from progenitor cells* 
Overview: The purpose of the study herein is to evaluate the potential of engineered 
vascular tissues as a platform to study the Notch signaling pathway in a 3D co-culture 
system. Smooth muscle cell lines from rats (A-10) and a multipotent cell line from mice 
(10T1/2) were used to compare their interaction with the human coronary artery 
endothelial cells (HCAEC) in a Notch signaling context. Notch activation was 
characterized by both gene and protein expression of known Notch downstream targets 
using qPCR and immunofluorescence microscopy. Physical characterization of the fibrin 
gel was also reported. 
3.1 Summary 
The main impetus of vascular tissue engineering is clinical translation; but an equally 
appealing and impactful use of engineered vascular tissues is as preclinical testing 
platforms for studying vascular disease and developing therapeutic drugs and 
understanding of physiologically relevant vascular biology. Developing model engineered 
tissues will aid in narrowing the significant knowledge gaps in functional tissue formation, 
which is regulated by intricate cell signaling in a three-dimensional space. In this study, 
tubular engineered vascular tissues were fabricated using crosslinked fibrinogen as a 
scaffold and non-differentiated embryonic rat vascular smooth muscle cell line (A10 cells) 
and mouse embryonic multipotent mesenchymal progenitor cell line (10T1/2 cells) as cells 
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embedded in the gel were unable to significantly contract the tissue compared to fibrin-
only gels due to their undifferentiated state. In contrast, 10T1/2 cells differentiated with 
TGFβ1 to a vascular lineage were able to contract the tubular gel significantly owing to the 
contractile cytoskeletal stress fibers. Owing to its vital role in vascular morphogenesis, 
tissue specification and maturation, Notch signaling studies in engineered vascular tissues 
from A10 cells demonstrated cis-inhibition while 10T1/2 cells activated Notch and its 
downstream targets Hes-1 and the smooth muscle α-actin genes.  Taken together, this study 
showed that: (i) contrary to the previously accepted notion, cell-type is important to gel 
contractions, (ii) In engineered vascular tissues, Notch signaling is highly context-
dependent where cis-inhibition muted signal activation in A10 vascular cells while Notch 
was fully activated in 10T1/2 cells. These findings may provide insights to fabricate 
functional vascular tissues.   
3.2 Introduction  
In vascular tissue engineering strategies, scaffolds and cells are the two critical 
components. An ideal vascular tissue engineering scaffold is expected to provide both the 
mechanical support and the microenvironment that is conducive for seeded cells1. The 
mechanical support, which is a temporary one until cells produce their own structural 
matrix, is readily provided by choosing a scaffold material of synthetic origin (e.g. 
biodegradable polyesters2, poly(ester) amides3 and polyurethanes4). The benefit in 
selecting synthetic scaffolds is to maximize flexibility on the material selection with 
acceptable initial mechanical properties. The scaffold microenvironment, on the other 
hand, provides appropriate cues for cells to differentiate and maintain a differentiated 
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phenotype of vascular smooth muscle cell (SMC) which are often regulated by several 
signaling processes3, 5. Protein-based scaffolds (e.g., decellularized tissues, collagen, fibrin, 
and elastin) are best suited for providing a better microenvironment than synthetic materials 
since they provide potential binding sites for receptors. By selecting different synthetic and 
protein-based biomaterials, several investigators have reported top-down design of 
engineered vascular tissues (recently reviewed in6). Although mechanical properties and 
matrix deposition in engineered vascular tissues have been studied7-9, the role of scaffolds 
and the source of cells to activate important signaling processes are notably lacking.  
Fibrin gel is an important naturally occurring vascular tissue engineering scaffold that has 
been studied with respect to entrapped smooth muscle cells migration and proliferation and 
to a lesser extent extracellular matrix deposition (abundant collagen and detectable elastin). 
Unlike many vascular scaffold materials, fibrin is highly stretchable, exhibits non-linear 
mechanics, and displays unusual effect since there is a dramatic decrease in volume upon 
stretching thus displaying negative compressibility10. Highly compacted fibrin matrix has 
also acceptable mechanical properties11.  These features of fibrin are beneficial for vascular 
tissue engineering scaffolds that are routinely subjected to circumferential stretching forces 
during the maturation process. Similarly, unlike synthetic hydrogels, fibrin provides 
binding sites for many growth factors such as fibronectin, hyaluronic acid, and von 
Willebrand factor12. Furthermore, fibrin has an advantage since it is biocompatible, 
biodegradable, and the fact that the precursor fibrinogen can easily be obtained from 
autologous blood. Previous studies have utilized fibrin gel to fabricate vascular tissues with 
some success in animal models11, 13, 14.  
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In light of the many benefits (both mechanically and biologically) of fibrin, it will be 
beneficial to evaluate fibrin scaffold with regards to maintaining a differentiated vascular 
SMC phenotype and Notch signaling.  The vascular SMC is the main cellular component 
to fabricate an engineered vascular tissue. The limited proliferative capacity of human adult 
vascular cells and their slow rate of extracellular matrix (ECM) proteins production are 
challenges to fabricate a biologically functional engineered tissue.  However, other sources 
(embryonic stem cells, induced pluripotent stem cells, or adult stem cells) can be 
differentiated into vascular SMC15. Regardless of the source, phenotype modulation of 
SMC is an important design goal since these cells switch between the contractile phenotype 
characterized by well-organized cytoskeletal and contractile marker proteins and the 
synthetic phenotype characterized by increased proliferation rate and matrix production16, 
17. The transition between the two states is not well-defined but is a continuum and several 
signaling processes may be in involved. Notch signaling is a dominant process in vascular 
specification and cell-fate determination. The expression pattern of the Notch receptors and 
their ligands differ with the type of tissue. In the context of vascular tissue, Notch3 is the 
major receptor found on arterial SMCs, and Jag1 is the major ligand expressed by 
endothelial cells (EC) 18, 19; however the expression of these proteins can differ throughout 
development and disease. Notch is recognized as an important regulator of vascular SMC 
phenotype. Our lab and others have previously shown that Notch signaling leads to 
expression of contractile vascular SMC markers20-23. On the other hand, other studies have 
shown that this pathway inhibits SMC differentiation to a contractile phenotype via 
upregulating the expression of Hairy-related transcription factors (HERT) (reviewed in 
ref24) which is a downstream target of notch signaling. These studies certainly indicated 
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that the outcome of the Notch pathway activation is heavily dependent on cellular and 
molecular contexts. Identifying these contexts will advance our understanding of this 
pathway and how it regulates vascular SMC phenotype and will improve our chances in 
producing better engineered vascular tissues. In view of all the above, the aim of the current 
study was to compare two different cell types (non-differentiated embryonic vascular 
smooth muscle cell line (A10 cells) and embryonic multipotent mesenchymal progenitor 
cell line (10T1/2 cells) in fibrin-based vascular tissue for their gel contraction and their 
Notch signaling behaviors. 
3.3 Materials and Methods 
3.3.1 Cell culture and tissue fabrication.  
Non-differentiated embryonic vascular smooth muscle cell line (A10 cells) and embryonic 
multipotent mesenchymal progenitor cell line (10T1/2 cells) were purchased from ATCC 
and maintained in Dulbeco’s Modified Eagle’s media (DMEM) (Thermofisher) containing 
5% Fetal Calf Serum (FCS) (Thermofisher) and 1% penicillin/streptomycin by volume. 
Human coronary artery endothelial cells (HCAEC) were obtained from Lonza and 
maintained in EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM. Cells were 
passaged when they reached 80% confluency and media changes were regularly performed 
according to supplier’s recommendations. To fabricate the fibrin-based tissues, cells were 
trypsinized with trypsin-EDTA 0.05% (Thermofisher) for 2 min and then suspended in 
DMEM. The cells were counted, and the appropriate volume was taken from the cell 
suspension to give a final cell content that varied between 0.5 to 1 million cells/mL of 
construct. The cells were then centrifuged at 1200 rpm for 5 min, the supernatant aspirated 
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and cells resuspended in 450 µL of media. To that, 10 µL of 2 M CaCl2, 40 µL of 50 mg/mL 
ε-aminocaproic acid (ε-ACA) (Sigma-Aldrich), and 2 µL of 1U/µL Thrombin (MP 
biomedicals) were added. This cell suspension was kept on ice until it was mixed with ice-
cold 500 µL solutions of 4, 6 or 8 mg/mL bovine fibrinogen (MP Biomedicals). Right after 
mixing the two solutions, the mixture was transferred into a clean glass mold that had been 
disinfected with 70% EtOH, dried and then incubated in a 5% solution of Pluronic F-127 
(Sigma-Aldrich) for an hour at room temperature. The mold is composed of a glass shell 
with an inner diameter of 1cm, and a glass mandrel with an outer diameter of 4mm. Two 
Teflon plugs were used to seal the ends of the glass shell and position the mandrel in the 
center. The mold was then transferred to an incubator at 37 ºC for 1.5 h for crosslinking.  
Initial dimensions of the constructs reflected the dimensions of the mold; however, they 
changed as the constructs shrunk in culture. Tissue disks to measure water mass loss were 
made the same way as mentioned previously; however, a cylindrical tube was used instead 
of the mold. 
For co-culture experiments with ECs, A-10 or 10T1/2 cells were seeded in 6 mm plates 
(Corning) at a density of 0.3×106 or 0.5×106 cells/plate, respectively, and left overnight in 
the incubator to attach. The following day ECs were seeded on top of the A-10 and 10T1/2 
cells at a density of 0.5×106 cells/plate. The co-cultured plates were maintained in a mixture 
of DMEM and EGM2 at a ratio of 1:1. For Notch signaling studies, the Notch inhibitor 
DAPT was used at a concentration of 15 µM for 3 days cultures.  For seeding ECs in the 
lumen of tissues, small pieces of sterile gauze were incorporated into the fabrication of the 
tissues on either end to facilitate tying the ends of the tubes closed with sterile dental floss 
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without breaking. Prior to seeding ECs in the lumen, one end of the tissue was tied with a 
sterile dental floss, then 0.5 mL of media containing 1×106 cells/mL was pipetted into the 
lumen and the other end of the tissue was tied with another piece of sterile dental floss. The 
tissue was given 4 hours in the incubator and then turned 180º to allow the cells to attach 
all around the lumen. Then the tissue was left overnight in the incubator after which the 
ties were cut to allow the culture media into the lumen. 
3.3.2 Tissue water loss and vitality assays.  
Tissue disks were cultured in media for a period of 12 days. During the culture period, the 
tissues were taken out of culture, blotted on a sterile paper towel, placed in a sterile tube 
and weighed every 3 days. To assess the vitality of the tissues, tissue disks were cultured 
in 12 well plates for a period of 12 days and their viability was measured every 3 days 
using resazurin blue (Sigma-Aldrich) assay. Culture medium was aspirated and replaced 
with 1 mL of sterile PBS containing 1.75 µg/mL resazurin blue and incubated at 37 ºC for 
5 h. After that, 100 µL from each well was taken and placed in a 96 well plate and the 
absorbance was measured at 570 and 600 nm against a blank. 
3.3.3 Scanning electron microscopy (SEM) imaging of fibrin gels.  
Fibrin gels were prepared by mixing 50 µL of ice-cold fibrinogen solution (2mg/mL) with 
50 µL of ice-cold DMEM containing 1 U thrombin. The 100 µL mixtures were quickly 
pipetted onto aluminum foils in a 24-well plate culture wells and then transferred to a 37°C 
incubator to cross-link for 1.5 h. After incubation, 0.5 mL of PBS was added to each well 
to prevent the gels from drying. The gels were incubated at 37 °C for 3 days after which 
they were fixed with 4% paraformaldehyde for 30 min. Following fixation, the gels were 
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washed 3 times with distilled water, and serially dehydrated with EtOH in water (50%, 
75%, 95% and 100%) for 15 min each. After dehydration with EtOH, the gels were serially 
dehydrated with hexamethyldisialazane (HDMS) (Sigma) in EtOH (50%, 75%, and 100% 
twice) for 15 min each. After removing the HDMS, the gels were allowed to dry overnight 
at room temperature, sputtered with gold/palladium, and then imaged with an SEM (LEO 
1530; Zeiss, Oberkochen, Germany). 
3.3.4 Western blotting.  
A-10 cells treated with 2 ng/mL TGF-β1 for 3 days were washed 3 × with ice-cold 
phosphate-buffered saline (PBS) then harvested in ice-cold RIPA buffer (50 mM Tris-Cl 
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 0.25% (w/v) sodium 
deoxycholate and 0.1% (w/v) SDS pH: 7.5) containing protease inhibitor cocktail (Roche) 
and 1 µM Phenylmethanesulfonyl fluoride (PMSF). The cells were kept on ice for 15 min 
to allow for lysis to complete. Lysates were centrifuged at 12000 rpm for 15 min. The 
pellets were discarded, and the supernatants’ protein contents were quantified using the 
Pierce BCA protein assay protocol (Pierce). Protein samples were resolved by SDS-PAGE 
and transferred onto a nitrocellulose membrane (Pall life sciences). Blocking the membrane 
was performed with 5% BSA (Sigma-Aldrich) in PBS with 0.1% Tween-20 (PBS-T) and 
Western blotted with the Acta2 primary antibody (1:1000) (Santa Cruz Biotech) diluted in 
5% BSA in PBS-T overnight at 4º C. The blots were then washed 2 × with PBS-T for 5 
min each, and 1 × with PBS for 5 min, followed by incubation with goat anti-mouse 
secondary antibody (1:5000) diluted in 5% BSA in PBS-T for 1 h at room temperature. 
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Finally, the blots were washed as before and incubated with Supersignal west pico 
chemiluminescence substrate (Pierce) and developed using ChemiDoc XRS+ (BioRad). 
3.3.5 Immunofluorescence microscopy and histology.  
For 2D studies, cells were seeded in 6-well plates containing a coverslip at a density of 2.5 
× 105 cells per well in complete media. The next day, the cells were treated with 2 ng/mL 
TGF-β1 for a period of 3 days. After that, the cells were washed with 37ºC PBS and fixed 
with 4% paraformaldehyde in PBS for 15 min at room temperature. The paraformaldehyde 
solution was aspirated, and the cells washed 3 × with PBS at room temperature. For tissue 
studies, the tissues where washed with 37º C PBS and then fixed with 4% 
Paraformaldehyde at RT for 1 h. The tissues were then washed with PBS 3 times and 
incubated at RT in a 15% and then in a 30% solution of sucrose for 30 mins each, washed 
with PBS and then dabbed on a tissue to remove excess liquids. After that, the tissues were 
immersed with OCT compound (Fisher) and transferred into -80º C isopropanol. Tissue 
sections were obtained by using a Leica cryostat (Leica) and then were washed with PBS 
3 times for 5 mins each to remove OCT compound. Cells/tissue were permeabilized with 
a 0.2% (v/v) Triton x-100 in PBS for 15 min at room temperature and then blocked with 
5% BSA in PBS-T for 1 h. The blocking solution was then aspirated, and 100 µL of primary 
antibodies of Hes1, Acta2, Smtn, Notch3, Myh11, ColI, ColIII, Cnn1, or Jag1 (Santa Cruz 
Biotech) (1:100) in 5% BSA PBS-T were placed on the coverslip and covered with a piece 
of parafilm and placed in a humid environment at 4º C overnight. In order to rule out a 
nonspecific signal, IgG antibodies against rabbit and mouse species have been used as 
controls at the same dilution ratio. The next day the cells/tissues were washed 2 × with 
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PBS-T and once with PBS for 5 min each, then incubated with the corresponding secondary 
antibody (1:250) for 1 h at RT. The coverslips were then washed 2 × with PBS-T and once 
with PBS and incubated with 2 µg/mL DAPI for 5 min, washed with PBS 3 times and 
mounted with mounting media. The images were taken by a compound fluorescent ZeissZ1 
microscope (Zeiss).  
Histological microscopy was performed by taking tissue sections and staining them with 
hematoxylin for 3 min, and then incubating with tap water for 5 min, followed by washing 
with acid ethanol (0.3% HCl in 70% EtOH). Excess fluids were removed by blotting the 
slides with a paper towel before staining with eosin. The tissues were incubated in Eosin 
for 1 min, and then 3 times in 95% ethanol for 5 min followed by 3 times in 100% ethanol 
for 5 min each. Slides were allowed to dry and then visualized using a Nikon Eclipse TS100 
microscope (Nikon). 
3.3.6 RNA isolation and qPCR.  
For the engineered tissues, approximately 50 mg of tissue was placed in each Eppendorf 
tubes and frozen at -80 ºC for at least an hour, crushed by a pestle, and 750 µL of Trizol 
were added and then homogenized with a tissue homogenizer (BioBasic). The seeded 
endothelial cells (where applicable) in the engineered tissues were removed using a surgical 
scalpel, which is a well-established procedure. For 2D cultures, spent media was first 
aspirated and 500 µL of Trizol (Life Technologies) were pipetted for each 6 cm culture 
plate. The cells were then scraped and transferred to Eppendorf tubes. To separate 
endothelial cells from cocultures, cells were trypsinized using 1 mL of trypsin-EDTA 
0.05%, and then collected in a conical tube and centrifuged at 1200 rpm for 5 min. The cell 
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pellet was collected and resuspended in 1 mL of PBS containing 0.5% BSA and 1 × 107 
PCAM magnetic beads for 30 min on a tumbler at 4 ºC to separate the HCAECs from the 
10T1/2 cells. The magnetic beads were pulled down with a magnet and the 10T1/2 cells 
were transferred into a separate tube and centrifuged at 1200 rpm for 5 min. The 
supernatant was aspirated, and the cells were resuspended in 500 µL of Trizol to extract 
RNA. Lysates were left to incubate at room temperature for about 5 min. After that, 
chloroform was added at a ratio of 1:5 (chloroform:Trizol) and the samples were vortexed 
for 15 seconds then incubated at room temperature for 15 min. Samples were then 
centrifuged at 12000 g for 15 min at 4 ºC. The aqueous phase was transferred into another 
Eppendorf tube and Isopropanol was added at a ratio of 1:2 (isopropanol:Trizol) and 
incubated at RT for 10 min followed by centrifugation at 12000 g for another 10 min at 4 
ºC. The isopropanol was then aspirated, and the pellet was resuspended in 75% EtOH at a 
ratio of 1:2 (EtOH:Trizol) and centrifuged at 7500 g for 5 min at 4 ºC. This last step was 
done twice to wash excess salts. The pellet was then air-dried after the EtOh was removed 
and the pellet was dissolved in 25 µL of DEPC water and quantified with nanodrop 
(Thermo scientific). 1 ug of total RNA was used to synthesize cDNA using M-MLV 
reverse transcriptase kit (Promega) using the supplier’s protocol. For qPCR reactions, 1 µL 
of the formed cDNA was used in 10 µL reactions using the SsoAdvanced universal SYBR 
green supermix (Biorad) according to the manufacturer’s protocol. The qPCR reactions 
were carried out in a CFX96 Real-Time thermal cycler (BioRad) and GAPDH was used as 
a reference gene. 
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3.3.7 Gel swelling, water contact angle, and rheological properties.   
For fibrin gel swelling ratio determination, acellular fibrin discs were prepared from 3 
mg/mL fibrinogen as previously mentioned in the “Cell culture and tissue fabrication” 
section. The discs were then dabbed with a paper towel to remove excess water and then 
placed in a vacuum desiccator 16h to dry the gels. The specimens were weighed to obtain 
the initial mass (mi) for each gel and were placed in 1mL PBS and placed in an incubator 
at 37º C for 2 h. After that, the gels were removed from the PBS and dabbed on a paper 
towel and weighed to measure the final mass (mt). The % swelling  ratio was calculated 










Water contact angles were measured by a Kruss DSA100 Drop Shape Analyzer. A fibrin 
gel was prepared using 3 mg/mL fibrinogen in ice-cold PBS and 2 mM CaCl2. To that, 2 
µL of 1U/mL Thrombin was added and the solution was quickly transferred onto a 
microscope slide and spread on its surface before gelling. The slide was incubated at 37 ºC 
to accelerate crosslinking. After 1 h, the glass slide was dabbed on a paper towel and placed 
in a desiccator overnight to dehydrate the gel. The contact angles were measured in 
triplicate after allowing the water droplet to equilibrate on the gel for 15 sec. For 
rheological testing, a parallel plate rheometer operating at 37 ºC was used. The plates (25 
mm diameter) were set up at a 1mm distance and 500 µL ice-cold solution of 3 mg/mL 
fibrinogen in PBS, 2 mM CaCl2, and 2 U Thrombin was injected between the plates. After 
the sample gelled for 30 min, amplitude sweep tests were performed. 
61 
 
3.3.8 Statistical analysis.  
Where applicable, data are presented as the means of at least three independent experiments 
and the error bars are the standard deviation from the means. Statistical significance was 
calculated either using t-tests or ANOVA depending on experimental design. Tukey’s 
multiple comparison tests were used for post-hoc statistical analysis. Differences were 
considered significant if p < 0.05.  
3.4 Results and Discussion 
3.4.1 Fibrin gel swelling ratio, water contact angle, and rheological properties.  
Since fibrin gel is used as bioadhesive in surgeries for hemostasis, wound closure, sealant, 
and scaffold for tissue engineering, its characterization as a biomaterial is well-reported 
(reviewed in Ref 25). However, property variability may still exist depending on the 
sources, the fibrinogen concentration used to prepare the gel, and the presence of 
crosslinking agents other than thrombin 26, 27. Therefore, the swelling ratio, wettability, and 
rheological properties were determined for fibrin gels prepared from 3mg/mL solution. 
While direct comparison with literature was not straightforward due to variations in 
fibrinogen concentration, additional crosslinking agent, crosslinking time etc, data 
collectively presented in Tables 3.1 and 3.2 and Figure 3.1 indicated that the properties of 
the fibrin gels were, in general, consistent with reported values in the literature27-29. For 
instance, the percent swelling ratio of fibrin gel is reported to be between 100% to 250% 




Table 3.1. Swelling ratio of five fibrin gel disks prepared from 3 mg/mL fibrinogen. 
 
Fibrin is more hydrophobic than its precursor fibrinogen and its water contact angle is 
reported to be between 63º and 74º when measured on a dry film28. Contact angle is 
between 44º and 48º likely contributed to by the 15 sec that the water droplet remained on 
the fibrin film before taking the contact angle reading as suggested by the operating manual 
(pre-wetting step). On a hydrophilic polymer, such a delay seemingly minor could make a 
significant difference (Table 3.2). 
Table 3.2. Fibrin water contact angle. 
 Contact angle (º) 
Test #1 43.6 
Test #2 47.5 
Test #3 47.6 
Mean 46.3 ± 2.3 
 
The storage modulus (G’) vs. strain amplitude data obtained from rheological measurements 
of a fibrin gel prepared from 3mg/mL fibrinogen concentration indicated that the storage 
 Gel 1 Gel 2 Gel 3 Gel 4 Gel 5 
Initial fibrin gel weight (mg) 14.4 14.2 13.9 10.6 10 
Final swollen fibrin gel weight 
(mg) 
31.9 32 35 22.5 23.2 
Swell ratio (%) 121.5 125.4 151.8 112.3 132.0 
Mean swelling ratio (%) 128.6±14.8 
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modulus ranged from 85Pa to 110Pa without significant strain hardening effect (Figure 3.1). 
This was similar to reported values for pristine fibrin gels 27. 
 
Figure 3.1. Storage modulus vs. amplitude sweep results for a fibrin gel prepared from 3 
mg/mL fibrinogen concentration (measurements were taken at 37 ºC) 
 
3.4.2 Smooth muscle marker expression, tissue viability and collagenous matrix 
synthesis.  
In this study, non-differentiated embryonic rat vascular smooth muscle cell line (A10 cells) 
and mouse embryonic multipotent mesenchymal progenitor cell line (10T1/2 cells) were 
compared as model vascular cells. Since A10 cells are neointimal stem-derived smooth 
muscle cells (SMC), SM-α actin expression with and without the presence of TGF-β1 − a 
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growth factor that differentiates vascular SMC into a contractile phenotype32  − was tested. 
Protein analysis for SM-α actin (Acta2) using Western blot showed that treating A10 cells 
with 2 ng/mL TGF-β1 for 3 days did not affect the expression level of Acta2 (Figure 3.2A). 
However, immunofluorescence microscopy showed increased fiber redistribution, 
alignment, and reorganization of Acta2 and smoothelin (Smtn) filaments suggesting a more 
mature contractile phenotype in response to TGF-β1 (Figure 3.2B). However, the role of 
TGF-β1 in A10 cells appeared to be post-translational since the expression at the protein 
level of Acta2 did not change. To assess the viability of A-10 cells in the engineered tissues, 
the absorbance of reduced resazurin for tissue cultures up to 12 days was measured (Figure 
3.2C, D). Figure 3.2C compares the differences in absorbance of cell-embedded fibrin gels 
prepared from 2, 3 and 4 mg/mL FBG and 0.5×106 cells, while Figure 3.2D compares 
fibrin constructs with the same FBG concentrations but with 106 cells. While tissue 
constructs containing 0.5×106 cells showed little differences in absorbance, those with 106 
cells showed an increased absorbance at day 3 and then a reduction in the absorbance for 
the rest of the duration. Overall, the metabolic activity of these tissues was stable over time. 
Resazurin is a widely used viability assay; however, its use in tissue viability assays is not 
very common as the diffusion of the dye into and out of the tissue is limited and therefore, 
the absorbance is mostly influenced by the cells on the surface of the tissues rather than 
those embedded in them. Despite this, the benefit of Resazurin is that due to its 
cytocompatibility, the tissue can be treated multiples times; thus, the metabolic activity of 





Figure 3.2. SMC marker and matrix protein expression, and tissue vitality and cell 
distribution. (A) Western blot analysis showing the level of expression of smooth muscle 
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alpha-actin (Acta2) with or without 2 ng/mL TGF-β1 for 3 days. (B) Immunofluorescence 
comparing control A-10 cultures and TGF-β1 treated A-10 cultures of cytoskeletal proteins 
Acta2 and Smtn. The bar diagrams on the right are the corresponding quantification of the 
images. Scale bar = 20 µm. (C) Resazurin cell viability assay of fibrin constructs with 
variable concentrations (2, 3, and 4 mg/mL) containing 0.5 million cells/m. (D) Resazurin 
cell viability assay of fibrin constructs with variable concentrations (2, 3, and 4 mg/mL) 
containing 1.0 million cells/mL. These tissues were cultured for 12 days. (E) Fluorescence 
staining of A10- and 10T1/2- containing tissues cultured for 1, 2 or 3 weeks. Nuclei were 
stained with DAPI and f-actin with Alexa-488 conjugated phalloidin in green. Sale bar = 
50 um. (F) Histochemical staining of fibrin-based tissue containing 10T1/2 cells cultured 
for one week in 3 or 4 mg/mL displayed at two different magnifications 4 and 10 ×. (G) 
10T1/2 in 3 mg/mL fibrin constructs treated with 50 µg/mL ascorbic acid and probed for 
collagen I and collagen III. Scale bar = 50 um. 
A cell viability test via absorbance measurement provides a global context for the activity 
of cells within the gels but is not instructive in terms of cell distribution which is important 
for remodeling and matrix deposition. Fluorescence microscopy images of tissue constructs 
containing A-10 cells and 10T1/2 cells taken at 1, 2, and 3 weeks during the maturation 
process are presented in Figure 3.2 E. Both cell types were uniformly distributed 
throughout the cross-section; however, the density of 10T1/2 cells within the construct 
remained to be higher than A-10 cells. Furthermore, it appeared that cells were forming 
bundles at the lumen and ablumen of the tubular construct, as evidenced by the intense 
staining in those regions. H&E staining of tissues containing 10T1/2 cells and matured for 
1 week agreed with the fluorescence microscopy images showing the distribution of cells 
throughout the cross-section (Figure 3.2 F). 10T1/2 cells have been studied 3 as SMC 
progenitor cells and are believed to be a good model to study SMC phenotypic switching. 
Engineered tissues started to produce collagenous matrix proteins (Collagens I and III) 
which was further enhanced with 50 µg/mL ascorbic acid treatment (Figure 3.2 G). While 
collagen I is the main type of collagen in the vasculature, collagen III is also important as 
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its absence or imbalance has been shown to be linked to Vascular Ehlers-Danlos syndrome 
of arteries 33, 34. 
3.4.3 Gel contraction kinetics and fibrous gel stability.  
When fibrin and collagen gels are used as a scaffold for tissue engineering, dimensional 
contraction is often observed in the presence of fully differentiated primary cells35-38. 
However, it is unknown if non-differentiated embryonic and mesenchymal progenitor cells 
can exert sufficient contraction forces on the gels to bring macroscopic dimensional 
changes. When non-differentiated embryonic vascular smooth muscle cells were 
embedded into the gels prepared at different concentrations, a reduction was observed in 
the volume of the fibrin constructs with 2mg/mL concentration which was more noticable 
in comparison to the other concentrations after 7 days in culture (Figure 3.3A). The effect 
of fibrinogen concentration with embedded A-10 cells on compaction kinetics was studied 
at 500, 000 cells/mL and 106 cells/mL (Figures 3.3B, C).  For both cell densities and at all 
fibrinogen concentrations, the cylindrical disk gels contracted drastically, and the fractional 
mass of the gels decreased significantly during the first 3 days of culture (p<0.05). From 
day 3 to 12, all tested fibrinogen concentrations with 500, 000 cells/mL showed significant 
differences amongst them at each time point (p <0.05). However, when each concentration 
was compared at different time points from day 3 to 12, there was no statistical significance 
on gel contraction kinetics (p>0.05).  When the cell concentration in the gel was increased 
to 106 cells/mL (Figure 3.3C), a similar behavior was observed except that significance 
only existed between 4mg/mL and 2 mg/mL fibrinogen concentration at each time point 
between 3 days and 12 days (p<0.05). The role of cell numbers at a fixed fibrinogen 
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concentration was also studied (Figures 3.3D, E). The dimensional contraction was 
significant until day 3 and remained unchanged for the subsequent 9 days (p<0.05). It is 
worth mentioning that the presence of cells did not change the dimensional contractions of 
the fibrin gels compared to the fibrin-only gels. While cell-induced contractions of fibrin 
gels were expected due to the anticipated force exerted by cells, the fact that these gels 
contract to the same level even without cells implies that other factors are in play. The gels 
have a large amount of water and were assumed to be incompressible; thus, the observed 
contraction is primarily caused by water expulsion (syneresis) from the gel rather than 
fibrin degradation since a plasmin inhibitor (ε-aminocaproic acid) was present in the media 
throughout these experiments. As additional evidence, fibrin gels were cultured for 3 days 
and SEM images were taken to visualize fiber morphology (Figures 3.3F, G). Clearly, the 
fibers were morphologically intact, suggesting the absence of degradation notwithstanding 
the volume change. Although one previous research suggested the absence of compaction 
in a cell-free fibrin gel39, this data suggests the contrary. It is likely that crosslinking of 
fibrinogen into fibrin causes internal stress leading to the unfolding of α helices into β 
sheets, thus compacting the network 40-42. Although fibrin gel compaction at a fixed time 
is previously studied35, gel compaction kinetics is rarely investigated 43. In fact, most 
studies investigated gel compaction after weeks of culturing in the presence of fully 
differentiated cells; however, the time required to reach constant compaction has not been 
studied. Data in this study suggested that for all the fibrinogen concentrations and the cell 
numbers embedded in the gels, the gels reached a steady-state mass after 3 days of culture.  
Given the current understanding that fibrin gels have accelerated compaction in the 
presence of cells, significant differences on both the compaction kinetics and in response 
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to cell number variations was expected. Since the gels without cells compacted similar to 
the gels with cells, this was attributed to the nature of the undifferentiated A-10 cells. 
Compared to fully differentiated cells used in previous studies35-38, A10 cells are immature 
cells that may not have sufficiently organized cytoskeletal protein fibers to bring significant 




Figure 3.3. Tissue contraction, mass loss and SEM analysis of fibrin fibers. (A) 
macroscopic comparison of compacted fibrin gels of different concentrations (2, 3, and 4 
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mg/mL) at day 0 and after 7 days in culture. (B) mass loss in constructs containing 0.5 
million cells in different concentration of fibrinogen (2, 3, and 4 mg/mL) and (C) mass loss 
of constructs containing 1 million cells in different concentrations of fibrinogen (2, 3, and 
4 mg/mL) as a function of time. (D) mass loss of 3mg/mL FBG and (E) 4mg/mL FBG 
containing 0.5 million and 1 million cells compared to constructs without cells as a function 
of time. (F) and (G) show the fibrous structure of 1 mg/mL fibrinogen after 3 days in culture 
at 15,000 and 35,000 magnifications, respectively. Scale bar in (F) = 1 µm. Scale bar in 
(G) = 0.2 µm. 
 
3.4.4 SMC differentiation of embryonic multipotent mesenchymal progenitor cells 
and gel contraction.  
The preceding gel contraction kinetics was conducted using A-10 cells. The A10 cells 
derived from the thoracic aorta of embryonic rat are non-differentiated, neonatal and 
neointimal vascular smooth muscle cells while 10T1/2 cells are mouse embryonic 
multipotent mesenchymal progenitor cells. 10T1/2 cells share similar differentiation 
characteristics with mesenchymal stem cells and have been shown to differentiate into 
mature vascular smooth muscle cell lineage under appropriate conditions44, 45. For this 
purpose, 10T1/2 cells were embedded into tubular fibrin gels with and without 2ng/mL 
TGF-β1, matured them for one week and monitored tissue contraction and differentiation 
into a mature vascular SMC. The rationale for choosing 10T1/2 cells instead of A10 cells 
is based on the previous findings that TGF-β1 upregulated SMC contractile protein in these 
cells3, 45, though the induction of these markers in fibrin gel has not been demonstrated 
before. As presented in Figures 3.4A, B TGF-β1 induced significant contraction of the gels 
(p<0.001) where both the inner and outer diameters were reduced by 33%. As both gels 
were prepared from the same fibrinogen concentration and had the same cell numbers, 
contraction is attributed to cytoskeletal traction forces on the fibrin fibers caused by the 
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differentiation of the 10T1/2 cells towards a mature SMC. To ascertain differentiation, 
immunofluorescence microscopy images of smooth muscle α-actin (Acta2) and smoothelin 
(Smtn) were taken (Figure 3.4C). Although the expression of smooth muscle α-actin in 
the differentiated cells was similar to the human coronary artery smooth muscle cells, this 
marker is not specific to SMC as it is also expressed in other cells (e.g. myofibroblasts)46. 
The only marker unique to vascular SMC that is absent in myofibroblasts is smoothelin47, 
48, and hence this marker was selected in this study. As can be seen, these tissues expressed 
Acta2 and Smtn, suggesting a SMC lineage commitment in response to TGF-β1 treatment. 
On the other hand, SM-myosin heavy chain (Myh11) was undetectable (data not shown) 
and this was not surprising since it is a late-stage SMC differentiation marker and the 
culture time was only one week. This observation is also consistent with previous findings 
that longer-term cultures and biomechanical forces were required for Myh11 expression of 




Figure 3.4. Tissue contraction of fibrin-based 10T1/2 constructs treated with TGF-β1 and 
protein markers expression. (A) Macroscopic and microscopic images comparing control 
tissue with that treated with TGF-β1 showing the contraction of the tissue in response to 
TGF-β1. Contrast microscopy scale bar = 1 mm. (B) inner and outer diameter 
measurements of control vs TGF-β1 treated tissues. (C) Immunofluorescence staining of 
Acta2, Cnn1, Smtn, and ColIII in 10T1/2 tissue treated with 2 ng/mL TGF-β1 for 1 week. 
Scale bar = 50 um.  
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3.4.5 Activation of Notch signaling in engineered vascular tissues.  
Although TGF-β1 signaling pathway plays an important role in the SMC differentiation 
and maturation, the Notch signaling is one pathway that plays an important role in the 
differentiation, maturation, and function of vascular SMC20. The Notch family of receptors, 
Notch1 to Notch4, are single-pass transmembrane proteins consisting of both an 
extracellular domain (ECD) and an intracellular domain (ICD)49. Upon interaction with the 
Delta, Serrate/Jagged, Lag-2 (DSL) family of single-pass transmembrane ligands (Jagged1, 
-2 and Delta1, -3, and -4) expressed on neighboring cells, Notch undergoes proteolytic 
cleavage, which frees the ICD from the plasma membrane. This results in translocation of 
the ICD into the nucleus, where it forms a complex with the DSL family of transcriptional 
repressors (CBF1/RBP-Jk), removing the repression and allowing transcription of 
downstream target genes (Hes/Hey)50. Since the distribution of the Notch receptors and 
their ligands vary considerably in different tissues, it plays diverse roles in cardiovascular 
and cerebrovascular development and physiology24. The Notch pathway components 
relevant to vascular tissue engineering of arteries are Notch3 receptor and the ligand Jag1 
highly expressed in arterial SMC and EC, respectively 19.  In the present study, the effect 
of TGF-β1 and Jag1 on the activation of the Notch pathway in A-10 cells was studied via 
the transcription factor Hes-1, the downstream SMC-specific Myh11, and the matrix 
protein elastin gene expressions. In addition to a possible signal convergence between 
TGF-β1 and Notch signaling pathways51, the addition of TGF-β1 was to evaluate if these 
cells are able to produce an essential vascular ECM elastin based on previous finding that 
this growth factor was able to enhance elastin synthesis of human coronary artery smooth 
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muscle cells52. Figure 3.5A showed that treatment of A-10 cells by culturing them on either 
surface adsorbed Jag1 or by adding soluble TGF-β1 to the culture did not impact 
expressions of the tested genes in comparison to untreated control cultures (p>0.05). To 
investigate the role of the microenvironments (2D vs. 3D), A-10 cells and Jag1 were 
entrapped into the fibrin gel. Expression of the Notch ligand Jag1, the Notch signaling 
downstream transcription factor Hes-1 and SMC-specific marker Myh11 were either 
down-regulated or remained unchanged (Figure 3.5B), suggesting that Jag1 entrapment 
did not activate Notch in A10 cells. Studies have shown that Notch ligands are 
ubiquitinated by multiple ubiquitin ligases in order to properly activate the Notch receptor 
53 suggesting the importance of ubiquitination in the activation of the Notch signaling. 
Along with ligand ubiquitination, a mechanical pull force plays a critical role in ligand 
endocytosis and Notch signal activation. During endocytosis of the ligand by the signal 
sending cell, a pull force is generated by the ligand on the receptor of the signal receiving 
cell causing a conformational change. This then allows for the enzymatic cleavage of the 
Notch extracellular domain, and consequently to the propagation of the signal 54. Since the 
entrapped recombinant Jag1 ligand was not ubiquitinated, and there were no pulling forces 
subjected on the fibrin gel, the entrapped Jag1 ligand on its own is insufficient to activate 
the Notch signaling in this system. Moreover, the downregulation of Jag1 and Myh11 in 
the Jag1 treated group is occurring independently of the Notch signaling since Hes-1 that 
is a direct target of the Notch pathway was not activated. In Notch signaling, the ECD of 
the ligand expressed by signal-sending cell binds to the ECD of the Notch receptor 
expressed on the surface of adjacent vascular SMC (signal-receiving cell), leading to signal 
activation and subsequent expression of SMC contractile genes in a heterotypic cell-cell 
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contact manner 21-23. Since endothelial cells are the Notch signal sending cell in the 
vasculature, the effect of A10 cells and ECs coculture on the Notch pathway and contractile 
marker expression was also investigated. Gene expression data for Hes-1, Jag1, and Myh11 
for A-10, and EC in coculture shown in Figure 3.5C demonstrated that the expression of 
Hes-1 and Jag1 was reduced by half in the cocultured A10 cells compared to those cultured 
without EC. However, the expression of Myh11 did not change. In addition to qPCR, 
immunofluorescence microscopy results also showed that co-culturing A10 cells with EC 




Figure 3.5. Effect of TGF-β1  in 2D, Notch in 2D and 3D, and co-culture on gene and 
protein expression in A-10 cells. (A) Treatment of A-10 cells with Jag1 that is adsorbed to 
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the culture-ware (Ad) or treated with TGF-β1. (B) qRT-PCR of fibrin-based tissue 
containing A-10 cells with or without entrapped Jag1. (C) coculture of A-10 cells with 
Human coronary artery endothelial cells (EC). (D) Immunofluorescence of monoculture of 
A-10 cells or coculture of A-10 and HCAEC in fibrin-based tissue showing expression of 
Acta2 and Myh11 after 1 week. Scale bar = 50 µm. 
 
Data collectively presented in Figure 3.5 showed that (i) adsorbed and entrapped Jag1 did 
not activate Notch signaling in A10 cells, (ii) co-culturing A10 cells with coronary artery 
Jag1-expressing ECs also did not active Notch signaling in A10 cells, and (iii) extending 
the earlier observation in Figure 3.2A, neither TGF-β1 nor co-culturing with EC could up-
regulate smooth muscle differentiation markers. The first two findings, seemingly 
counterintuitive point to an important yet less known feature of Notch signaling, namely 
cis-inhibition55-57. In the Notch signaling context, a cell can be either a signal sending 
(ligand presenting) or signal-receiving cell depending on the relative abundance of receptor 
to its ligand on the same cell surface. However, when the Notch receptor binds to a ligand 
present on the same cell, signaling is inhibited. This phenomenon of cis-inhibition is an 
emerging hallmark of Notch signaling and relies on the relative abundance of the ligand 
and receptor. To ascertain if the ligand and receptor expression on the cell surface is of 
equal abundance causing signal inhibition, immunostaining of Notch3 and Jag1 was carried 
out. Figure 3.6A showed similar levels of expression of these proteins with and without 
TGF-β1 treatment. The rationale for TGF-β1 treatment is to evaluate the potential crosstalk 
that may exist between Notch and TGF-β through their downstream effectors CBF1 and 
SMAD2/351. Further quantification of the mRNA showed the levels of gene expression of 
these two markers are essentially the same (Figure 3.6B). Taken together, these are strong 
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evidence that Notch signaling is cis-inhibited in A10 cells and that these smooth muscle 
cells are not a suitable model to study Notch-induced differentiation and tissue maturation.  
 
Figure 3.6. Notch3 and Jag1 expression levels in A-10 cells. (A) Immunofluorescence 
microscopy images showing the levels of expression of the Notch3 receptor and its ligand 
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Jag1 in control cells versus TGF-β1 treated cells. Scale bar = 20 µm. Bar diagrams show 
the quantification of the red or green channel (AU = Arbitrary Units). (B) PCR results 
showing the gene expression levels of Notch3 and Jag1 in A-10 cells. 
 
Because of the cis-inhibition in non-differentiated embryonic rat vascular smooth muscle 
cell (A10 cells), the mouse embryonic multipotent mesenchymal progenitor cell (10T1/2 
cells) was chosen as an alternative model vascular cells for trans-activating Notch 
signaling. First, a co-culture system of 10T1/2 cells with human coronary artery EC was 
established in 2D using a 1:1 ratio of the respective cells growth medium.  After EC 
separation using PECAM-incubated magnetic beads, the differentiated 10T1/2 cells were 
probed for Notch signaling components and its downstream SMC target genes. Data 
collectively presented in Figure 3.7A demonstrated that Notch3 expression was 
significantly upregulated in the co-culture system with an accompanying Acta2 (p<0.05) 
while calponin remained unchanged (p>0.05). It is worth noting that Acta2 is a direct target 
of Notch3 signaling 24, 58 while calponin did not demonstrate that Notch3 was activated in 
differentiated 10T1/2 cells. In addition to the mono-culture controls, 10T1/2 cells were 
cultured in 1:1 ratio of DMEM:EC media to rule out the effect of EC media on Notch 
signaling (Data not shown). To establish a cause and effect relationship that links the 
activation of the Notch pathway in the 10T1/2 cells and the cocultured HCAECs, DAPT, 
which is a γ-secretase inhibitor of Notch signaling, was used (Figure 3.7B). The data shows 
that inhibition of the Notch signaling pathway prevented the upregulation of Hes1, Notch3 
and Acta2. These results confirm that HCAEC activated the Notch signaling in 10T1/2 
cells since in the absence of the inhibitor, the direct target of Notch activation Hes1 was 
upregulated and was, in turn, downregulated when the cells were treated with DAPT 
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(Figure 3.7B). Furthermore, the qPCR results were paired with immunofluorescence 
staining to see if the gene upregulation is reflected on protein levels. Probing for Hes1, 
Notch3, Acta2 and Smtn proteins showed increased expression of these proteins in the 
coculture, and downregulation is the presence of DAPT which is consistent with the PCR 
results (Figure 3.8, 3.9 & 3.10).  Extending the 2D culture findings, a fibrin-based tubular 
engineered vascular tissue was fabricated and ECs were seeded in the lumen (Figure 3.11). 
After one week in coculture, the ECs were scraped from the lumen using a scalpel and 
10T1/2 RNA was extracted from the tissue for qPCR (Figure 3.7C). Consistent with the 
2D qPCR data, the levels of Notch3 and its downstream target Acta2 gene expressions 
increased significantly (p<0.05); however, in contrast to the 2D results, calponin gene 
expression decreased. A fully differentiated and mature vascular SMC is characterized by 
expressions of the contractile marker proteins smooth muscle α-actin (Acta2), calponin 
(Cnn1), smooth muscle myosin heavy chain (Myh11) and smoothelin (Smtn).  Most of 
these contractile proteins are myocardin-induced expressions but Notch signaling has also 
been reported in response to contact-induced signaling with endothelial cells24. This study 
demonstrated that Notch3 signaling was activated when 10T1/2 cells are co-cultured with 
endothelial cells; however, due to cis-inhibition in A10 cells, Notch signaling was not 




Figure 3.7. Notch activation and inhibition in coculture of HCAEC and 10T1/2 in 2D and 
3D environments. (A) 2D qPCR of cocultured 10T1/2 and HCAEC after separation of the 
two cell types using magnetic beads coated with PCAM antibody. (B) qPCR of cocultured 
10T1/2 and HCAEC treated with 15 µM DAPT followed by separation of the two cell types 
using magnetic beads. (C) qPCR of cocultured 10T1/2 and HCAEC after mechanically 
removing the ECs by gently scrubbing the lumen with a scalpel. Groups with the different 





Figure 3.8. Coculture of 10T1/2 cells with endothelial cells upregulated Notch3 and its 
downstream transcription factor Hes1. (A) Immunofluorescence staining showing the 
expression level of Notch3 in cocultured cells and in cocultured cells treated with 15 μM 
of the Notch inhibitor DAPT for 3 days. (B) expression level of Hes1 in cocultured cells 
and in cocultured cells treated with 15 μM of the Notch inhibitor DAPT for 3 days. A 
monoculture of 10T1/2 cells was used as a control to assess the level of the target proteins 






Figure 3.9. Coculture of 10T1/2 cells with endothelial cells upregulated the smooth muscle 
cytoskeletal proteins Acta2 and Smtn. (A) Immunofluorescence staining showing the 
expression level of Acta2 in cocultured cells and in cocultured cells treated with 15 μM of 
the Notch inhibitor DAPT for 3 days. (B) expression level of Smtn in cocultured cells and 
in cocultured cells treated with 15 μM of the Notch inhibitor DAPT for 3 days. A 
monoculture of 10T1/2 cells was used as a control to assess the level of the target proteins 





Figure 3.10. Quantification of the fluorescence intensity from green channels of the 
immunostaining which correspond to the level of expression of the proteins from Figures 
3.8 and 3.9 using ImageJ software. 
 




















































































































































































Figure 3.11. Endothelial cell seeding on the luminal side of engineered fibrin-based tissues. 
The figure shows the absence of endothelial cells at the lumen (left image) compared to the 
presence of these cells stained with Cell Tracker Green and Cell Tracker Red (middle and 
right images). Scale bar = 50 µm. 
 
3.5 Conclusion.  
In this study, the use of fibrin-based vascular tissues to study cell behavior and signaling 
in two different cell lines, A10 and 10T1/2 cells was evaluated. Fibrin gel experiments 
showed that mass loss occurred in the first 3 days after tissue fabrication regardless of 
fibrinogen concentration or cell number, but the mass remained stable after 3 days. 
Comparing the two cell lines, 10T1/2 cells tend to persist longer in the wall of the 
engineered tissues; however, both cell lines showed better growth on the albumen and the 
lumen. Furthermore, the results show that A10 cells were irresponsive to the presence of 
the Jag1 ligand or to endothelial cells in the environment likely due to cis-inhibition of the 
Notch signaling. On the other hand, 10T1/2 cells responded to endothelial cell co-cultures 
by upregulating the Notch3 and Acta2 gene expression. In conclusion, fibrin-based tissues 
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are a good platform to study cell signaling in a physiologically relevant 3D environment; 
however, 10T1/2 cells appear to be better suited for evaluating the role of Notch signaling.  
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Chapter 4 
The effects of progenitor and differentiated cells on ectopic 
calcification of engineered vascular tissues* 
 
Overview this study describes the use of engineered vascular tissues as a model to study 
vascular calcification in an in vitro 3D environment. A multipotent mouse cell line (10T1/2) 
was used in its naïve and differentiated states to shed some light on the mode of 
calcification between the two phenotypes. Calcification was induced using an inorganic 
phosphate salt and was evaluated by using histology, qPCR, and immunofluorescence of 
calcification markers. Furthermore, the effect of Vitamin K and simulated elastin 
degradation on the engineered tissues was shown. 
4.1 Summary 
Ectopic vascular calcification associated with aging, diabetes mellitus, atherosclerosis, and 
chronic kidney disease is a considerable risk factor for cardiovascular events and death.  
Although vascular smooth muscle cells are primarily implicated in calcification, the role 
of progenitor cells is less known. In this study, engineered tubular vascular tissues from 
embryonic multipotent mesenchymal progenitor cells either without differentiating or after 
differentiating them into smooth muscle cells were fabricated and ectopic calcification 
through targeted gene analysis were studied.  Tissues derived from both differentiated and 
undifferentiated cells calcified in response to hyperphosphatemic inorganic phosphate (Pi) 
treatment suggesting that a single cell-type (progenitor cells and differentiated cells) may 
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not be the sole cause of the process.  Furthermore, Vitamin K, which is the matrix gla 
protein activator, was shown to have a protective role against calcification in engineered 
vascular tissues. The addition of partially-soluble elastin upregulated osteogenic marker 
genes suggesting a calcification process. Furthermore, partially-soluble elastin 
downregulated smooth muscle myosin heavy chain (Myh11) gene which is a late-stage 
differentiation marker. This latter point, in turn, suggests that SMC may be switching into 
a synthetic phenotype which is one feature of vascular calcification. Taken together, this 
approach presents a valuable tool to study ectopic calcification and associated gene 
expressions relevant to clinical therapeutic targets.   
4.2 Introduction 
Ectopic vascular calcification is a considerable problem in the elderly population, patients 
with type 2 diabetes, and chronic kidney disease1, and is linked to the risk of cardiovascular 
disease and mortality2-4. Calcification causes the hardening of blood vessels due to the 
accumulation of calcium-containing deposits in the lumen (intimal calcification) or the wall 
of the blood vessel (medial calcification). When calcification occurs in the wall of the 
vessel, especially in arteries, it causes the blood vessel to lose its recoil (loss of Windkessel 
effect) and leads to dysfunctional vascular tone, compliance mismatch, and increased blood 
pressure2, 5 whereas intimal calcification leads to narrowing of the blood vessel. Factors 
such as the absence of calcification inhibitors, apoptosis, bone demineralization, renal 
dysfunction, etc. that lead to an increase in the concentration of calcium ion (Ca2+) in the 
cytoplasm of vascular smooth muscle cells (SMC). Vascular calcification is a complex 
process that has been thought to occur passively with age as unregulated mineral 
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precipitation; however, it is now known to be a regulated process6-9. This process involves 
osteogenic gene marker expression and downregulation of contractile proteins by SMC and 
secretion of calcium-containing deposits onto the extracellular matrix.  
Prior studies10-13 have investigated the cell types within the vasculature that influence 
calcification. Some evidence pointed to resident progenitor mesenchymal cells that 
differentiated into osteogenic lineage 14-16 while others suggested de-differentiation and/or 
transdifferentiation of SMC into an osteogenic lineage17. In response to increased inorganic 
phosphate (Pi) concentration, SMC calcification proceeds by sodium-dependent phosphate 
transporter channel (PiT-1) and is accompanied by downregulation of SMC- and 
upregulation of osteogenic-gene markers 18. Clearly, the roles of differentiated and 
progenitor cells in vascular calcification is not well-understood. To date, vascular 
calcification studies have been predominantly conducted on cell culture and animal models 
and have been fundamental for the current understanding. However, conventional two-
dimensional cell cultures do not accurately replicate the intricate microenvironment of 
three-dimensional (3D) tissues, since tissue-specific extracellular architecture, mechanical 
and biochemical cues, and cell-cell communication are disrupted.  An alternative approach 
is the use of engineered vascular tissues that capture both the 3D organization and multi-
cellular complexity of the native system to fill a critical gap in the preclinical model tool 
chest between traditional cell culture and whole animal experiments and has the potential 
to accelerate the pace of basic biomedical research19. A number of important physiological 
characteristics of native tissues are preserved in an engineered vascular tissue; thus, 
providing models for specific disease conditions such as vascular calcification. While there 
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are reported studies to model atherosclerosis using engineered vascular tissues19, 20, studies on 
the calcification of the engineered tissue model are very limited21.  Therefore, the aim of 
the present work was to investigate the role of progenitor and differentiated cells in vascular 
calcification using an engineered tissue model.  
4.3 Materials and Methods 
4.3.1 Cell culture and model tissue fabrication. 
Embryonic multipotent mesenchymal progenitor cells (10T1/2 cells) (ATCC) were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermofisher) containing 
5% v/v Fetal Calf Serum (Thermofisher) and 1% v/v penicillin/streptomycin 
(Thermofisher). Media was changed every three days and cells were passaged when 
confluency reached 80%.  To fabricate engineered vascular tissues, two cell types were 
used: (i) undifferentiated progenitor 10T1/2 cells and (ii) 10T1/2 cells treated with 2ng/mL 
TGF-β1 for three days to differentiate them to a vascular lineage prior to tissue fabrication. 
Cultured cells were trypsinized with trypsin-EDTA 0.05% (Thermofisher) for 2 min and 
then suspended in DMEM. The cells were counted, and the appropriate volume was taken 
from the cell suspension to give a final cell count of 2 million cells/mL of tissue construct. 
The cells were then centrifuged at 1200 rpm for 5 min, the supernatant aspirated and cells 
resuspended in 450 µL of media. To that, 10 µL of 2 M CaCl2 and 40 µL of 50 mg/mL ε-
aminocaproic acid (ε-ACA) (Sigma-Aldrich), and 2 µL of 1U/µL Thrombin (MP 
Biomedicals) were added. This cell suspension was kept on ice until it was mixed with ice-
cold 500 µL solutions of 20 mg/mL bovine fibrinogen (MP Biomedicals) to give a final 
concentration of 10 mg/mL fibrinogen per construct. To study the effect of elastin on 
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calcification, 200 µg/mL partially-soluble bovine elastin (MP Biomedicals) was added to 
the cell suspension before mixing with fibrinogen solution. Right after mixing the two 
solutions, the mixture was transferred into a clean glass annulus that had been disinfected 
with 70% EtOH, dried and then incubated in a 5% solution of Pluronic F-127 (Sigma-
Aldrich) for 1 h at room temperature. The annulus was formed from 6 cm long glass shell 
with 6 mm outer diameter and a mandrel with 4 mm diameter. Two Teflon plugs were used 
to seal the ends of the glass shell and position the mandrel in the center. The assembly was 
then transferred to an incubator at 37 ºC for 1.5 h for crosslinking, taken out of the mold 
and cultured in DMEM for different tissue maturation times of 7 days to 14 days as per a 
previous study22. For calcification, the tissues were treated with 2.5 mM of inorganic 
phosphate in the form of sodium phosphate monobasic (NaH2PO4) after tissue maturation 
and continued for another week. Some tissues were further treated with 20 µg/mL vitamin 
K.  
4.3.2 Histology and Immunofluorescence microscopy. 
For 2D studies, cells were seeded in 6-well plates containing a coverslip at a density of 2.5 
× 105 cells per well. After 24 h, cells were either left untreated or were treated with 2 ng/mL 
TGF-β1 for 3 days before washing them with PBS and fixing them with 4% 
paraformaldehyde for 15 min at room temperature (RT). Engineered tissues were fixed for 
1 h, washed with PBS 3 times, and incubated first in a 15% and then in a 30% solution of 
sucrose for 30 min each at RT. The fixed tissues were then washed with PBS and dabbed 
using a paper towel to remove the excess liquid. After that, the tissues were immersed with 
OCT compound (Fisher) and transferred into -80 ºC isopropanol. Tissue sections (10 µm 
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thickness) were obtained by using a Leica cryostat (Leica) and placed on microscope slides. 
The slides were washed with PBS 3 times for 5 min each to remove the OCT compound. 
Cells/tissue were permeabilized with a 0.2% (v/v) Triton x-100 in PBS for 15 min at room 
temperature and then blocked with 5% BSA in PBS-T for 1 h at RT. The blocking solution 
was then aspirated, and 100 µL of the appropriate primary antibodies (anti-ACTA2, -
CNN1, -MYH11, -COLI, -ELN, -OPN antibodies from mouse, and anti-SMTN antibody 
from rabbit (Santa Cruz Biotech)) (1:100) in 5% BSA PBS-T were placed on the coverslip 
and covered with a piece of parafilm and placed in a humid environment at 4º C overnight. 
The cells/tissues were washed 2 × with PBS-T and once with PBS for 5 min each, then 
incubated with the corresponding secondary antibody (Alexa-488 conjugated goat anti-
mouse and Alexa-594 conjugated goat anti-rabbit (ThermoFisher)) (1:150)  in 5% BSA 
PBS-T for 1 h at RT. The coverslips were then washed 2 × with PBS-T and once with PBS 
and incubated with 2 µg/mL DAPI for 5 min, washed with PBS 3 times and mounted with 
anti-fade mounting media. The images were taken by Zeiss Z1 fluorescent microscope. 
Quantification of the fluorescence intensity was performed using the ImageJ software. The 
green channel (target protein) and blue (DNA) channels were quantified separately, and 
then the relative quantification was obtained by dividing the intensity of the green channel 
by that of the blue channel. The treatments were done in triplicates, and an average of 3 
representative images was taken for quantification of figure 1A. Histological staining was 
performed by staining with Alizarin red S (40mM, pH 4.1) for 30 min. Tissue sections were 
then washed with diH2O 5 times to remove the excess and unprecipitated dye. The excess 
liquid was removed by blotting the slides with a paper towel, allowed to dry, and then 
visualized using a Nikon Eclipse TS100 microscope. 
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4.3.3 RNA isolation and qPCR.  
For 2D cultures, spent media was aspirated and 500 µL of Trizol (Life Technologies) and 
cells were scraped and transferred to Eppendorf tubes. For engineered tissues, 
approximately 50 mg of tissue was placed in each Eppendorf tubes and frozen at –80 °C 
for at least an hour before crushing using a pestle and addition of 750 µL Trizol. The tissues 
were then homogenized with a tissue homogenizer (Bio Basic). Cells from 2D cultures and 
engineered tissues were lysed for 10 min, and chloroform was added at a ratio of 1:5 
(chloroform:Trizol) and the samples were vortexed for 15 sec then incubated at RT for 15 
min. Samples were then centrifuged at 4 ºC and 12000×g for 15 min. The organic phase 
was discarded, and the aqueous phase was transferred into another Eppendorf tube. 
Isopropanol was added at a ratio of 1:2 (isopropanol:Trizol) and incubated at RT for 10 
min followed by centrifugation at 12000×g for another 10 min at 4 ºC. The isopropanol 
was then aspirated, and the pellet was resuspended in 75% EtOH at a ratio of 1:2 
(EtOH:Trizol) and centrifuged at 7500×g for 5 min at 4º C. This last step was repeated 
twice to wash excess salts. The pellet was air-dried after the EtOH was removed, dissolved 
in 25 µL of DEPC water and quantified with nanodrop (Thermo Scientific). 1 µg of total 
RNA was used to synthesize cDNA using M-MLV reverse transcriptase kit (Promega) 
using the supplier’s protocol. For qPCR reactions, 1 µL of the formed cDNA was used in 
10 µL reactions using the SsoAdvanced universal SYBR green supermix (Bio-rad) 
according to the manufacturer’s protocol. The qPCR reactions were carried out in a CFX96 




Table 4. 1. Primers for mouse-specific mRNA amplification 
Gene Forward primer (5’→3’) Reverse primer (5’→3’) 
Spp1 ATCTCACCATTCGGATGAGTCT TGTAGGGACGATTGGAGTGAAA 
Alp1 CCAACTCTTTTGTGCCAGAGA GGCTACATTGGTGTTGAGCTTTT 
Runx2 CCAACCGAGTCATTTAAGGCT GCTCACGTCGCTCATCTTG 
Acta2 GGGCTATATAACCCTTCAGCG GCTGTCTTCCTCTTCACACAT 
Myh11 CTGGTTACATTGTAGGTGCCA GCGAGCAGGTAGTAGAAGATG 
Gapdh AAGGGCTCATGACCACAGTC GTGAGCTTCCCGTTCAGCTC 
 
Spp1- Osteopontin; Alp1- Alkaline phosphatase; Runx2 - Runt-related transcription factor 
2; Acta2- Smooth muscle-α-actin; Myh11- Smooth muscle myosin heavy chain 11. 
 
4.3.4 Statistical analysis. 
Data are presented as the means of at least three independent experiments, and the error 
bars are the standard deviation from the means. Statistical significance was calculated 
either using Student's t-test or one-way ANOVA depending on experimental design. 
Tukey’s multiple comparison tests were used for post-hoc statistical analysis for statistical 
significance, p-value of <0.05 was used. 
4.4 Results  
4.4.1 Cell and tissue differentiation. 
In this study, the potential of these cells to differentiate and express smooth muscle cell 
markers and associated extracellular matrix molecules in response to TGF-β1 treatment 
was tested. Figure 4.1A,B showed that during the 3-day treatment in culture plates, the 
cells differentiated as shown by the expression of ACTA2 and CNN1, but there was no 
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difference in the expression of MYH11, collagen type I (COLI), and elastin (ELN) likely 
due to the short treatment time.  
 
Figure 4.1. Differentiation of embryonic multipotent mesenchymal progenitor cell (10T1/2 
cells) into a smooth muscle cell lineage. (A) 10T1/2 cells in 2D culture plates were treated 
with 2ng/mL TGF-β1 for 3 days then stained with antibodies against ACTA2, CNN1, 
MYH11, COLI and ELN. The figure shows an increase in the expression of ACTA2 and 
101 
 
CNN1 but not MYH11, COLI or ELN. Scale bar = 50µm. (B) Quantification of the green 
channel relative to the blue channel of the immunostaining shown in Fig (A) above. (C) 
Comparison in gene expression of undifferentiated tissues, in situ TGF-β1-treated tissues, 
and tissues fabricated from differentiated cells after tissue maturation. The levels of 
expression of Acta2, Myh11 and Eln are shown. (D) Immunofluorescent staining of 
ACTA2, SMTN, MYH11 and ELN in differentiated and undifferentiated tissues. ACTA2 
staining shows that cell morphology changed to spindle-like structures in differentiated 
tissues, and expression of SMTN and MYH11 increased in the differentiated tissues. The 
expression of ELN does not appear to change. A = albumen; L = Lumen of the tubular 
tissues. Scale bar = 50 µm. For Figs. (B) and (C), data are means ± SD (n=3) and one-way 
ANOVA and Tukey’s multiple comparison tests were used for statistical analysis. * 
indicate statistical significance at p<0.05. 
 
Furthermore, differentiated cells exhibited a spindle-like morphology which is evident in 
the ACTA2 and CNN1 stained cells. This is a further indication that multipotent progenitor 
cells have differentiated into an SMC-like phenotype. For the fabrication of engineered 
vascular tissues, progenitor cells were either pre-differentiated and incorporated into the 
fibrinogen and matured to form the tissue or cells were mixed with fibrinogen and expected 
to differentiate in situ to SMC in the gel. Therefore, three different types of tissues were 
fabricated: (i) tissues containing undifferentiated progenitor cells which served as control, 
(ii) tissues that contained undifferentiated cells that were then treated with TGF-β1 in situ, 
and (iii) tissues with cells that were pre-differentiated prior to fabricating the tissues. 
Figure 4.1C shows the gene expression results of Acta2, Myh11, and Eln from these 
tissues. While pre-differentiating progenitor cells had the highest level of gene expression 
in the tissue, an attempt to differentiate progenitor cells in the tubular gel in situ by TGF-
β1 treatment did not lead to a significant increase in the expression of these genes. Even 
though multipotent progenitor 10T1/2 cells have been shown to differentiate into SMC in 
the presence of TGF-β122-25, the entrapment of these cells in the fibrin gel seems to prevent 
them from interacting with the ligand likely due to poor diffusion of the ligand into the 
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tubular tissue cross-section. On the other hand, differentiating the cells before entrapping 
them into the tissues ensures maximum interaction of the cells with the ligand, thereby 
producing vascular tissues with differentiated cells. Furthermore, immunofluorescence 
staining of tissue sections showed that the differentiated tissues had elevated levels of 
ACTA2, SMTN, and MYH11 but not ELN (Figure 4.1D). However, the significantly 
higher Eln gene expression in the differentiated tissues does not seem to translate to the 
protein level. Although this appears to be contrary to two-dimensional cell culture 
observations, it is not surprising in three-dimensional cell cultures where a similar behavior 
has been shown before 26 and mechanical stimulation via a bioreactor was needed for 
elastin protein synthesis 27. Consistent with Figure 4.1A, the cells in the fibrin gel exhibited 
elongated spindle-like morphology in the ACTA2 and SMTN stained cross-sections 
(Figure 4.1D), indicating a differentiated state of the tissues.  Since in situ differentiation 
attempts of the cells in the engineered tissues were not effective, it was not further 
investigated. In this study, qPCR data was complemented with immunofluorescence 
staining instead of Western blots. The reason is that the target protein extracts from cells 
in the fibrin gels were masked by RIPA buffer induced fibrin degradation during protein 
extraction. RIPA buffer contains sodium dodecyl sulfate which has long been known to be 
a potent anionic fibrinolytic detergent 28. Increasing the total protein loading from 50 µg to 
200 µg for Western blots did not make any difference and protein bands were still not 
detected (data not shown).    
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4.4.2 Calcification in engineered vascular tissues. 
It is well-known that high concentrations of inorganic phosphates (Pi) lead to calcification 
in vivo and in vitro 18, 29. Thus, engineered tissues were treated with hyperphosphatemic 
concentrations (2.5 mM) of inorganic phosphates for one week to evaluate if the engineered 
tissues can serve as a model for vascular calcification. As shown in Figure 4.2A, Pi-treated 
tissues were stained with Alizarin Red S which precipitates in the presence of calcium. The 
choice of Alizarin Red S staining over von Kossa staining is due to the specificity of the 
former to calcium cations to form a chelate while the latter is non-specific and binds anions 
(phosphates, sulfates, or carbonates)30.  It is evident that the Pi-treated engineered tissues 
contain calcium deposits regardless of whether the cells in the tissues were differentiated 
or not. Further evaluation of the tissues by immunostaining for the osteogenic marker 
osteopontin (OPN) confirmed that these tissues calcified in response to hyperphosphatemic 





Figure 4.2. Histological staining, gene, and protein expression of calcified engineered 
tissues. (A) Alizarin Red S staining (Scale bar = 0.1 mm) and osteopontin (OPN) 
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immunofluorescence (Scale bar = 50 µm) in both differentiated and undifferentiated tissues 
treated with hyperphosphatemic concentrations (2.5 mM Pi) for 7 days. Higher Alizarin 
Red S staining and Opn expression were observed in the presence of 2.5 mM Pi. The top 
and bottom panels are different areas of the tissues from repeated 
experiments. (B) Osteogenic- (Alpl, Spp1 and Runx2) gene expression of undifferentiated 
and differentiated tissues treated with 2.5 mM Pi for 2 weeks. (C) Osteogenic gene 
expression comparison of undifferentiated vs. differentiated tissues. (D)  vascular smooth 
muscle cell-markers (Acta2, Myh11) and elastin (Eln) genes expression in undifferentiated 
and differentiated tissues that have been treated with 2.5 mM Pi for 2 weeks. (E) Protein 
expression of SMC markers in undifferentiated and differentiated tissues treated with 2.5 
mM Pi for a period of 2 weeks. Protein levels remain unchanged in the undifferentiated 
tissues; however, elevated levels of staining were observed in the differentiated tissues that 
were relatively reduced in the presence of Pi. A = ablumen; L = Lumen. Scale bar = 50 µm. 
For Figs. B, C and D, data are means ± SD (n=3) and t-tests were used for statistical 
analysis. * indicates the significance at p<0.05. 
 
These results showed that both differentiated and non-differentiated engineered tissues are 
capable of calcifying, suggesting that a single cell-type (undifferentiated progenitor cells 
or differentiated cells) may not be the sole cause of the process. Given the Alizarin Red 
positive staining, the gene expression levels of osteogenic (Alp1, Spp1, Runx2), SMC 
(Acta2 and Myh11) markers, and SMC-derived matrix protein Eln in calcified engineered 
tissue models were explored (Figure 4.2B). In the undifferentiated tissues, Spp1 and Runx2 
genes were upregulated in response to Pi treatment (p<0.05) while Alpl was not responsive, 
suggesting a possible temporal effect. In the differentiated tissues, both Alpl and Runx2 
were significantly downregulated in response to Pi treatment (p<0.05) whereas Spp1 
remained unaffected. A comparison between undifferentiated tissues with differentiated 
tissues indicated that all the tested osteogenic genes were upregulated in the differentiated 
tissues (Fig 4.2C; p<0.05).  Since TGF-β1 was used to differentiate the progenitor cells 
into the vascular lineage, it suggests that these cells were able to express osteogenic genes 
as TGF-β1 is reported to recruit mesenchymal stem cells to a vascular injury site where 
these cells upregulate some of the osteogenic lineage genes15. However, the observed 
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osteogenic gene expression was not accompanied by a corresponding calcification since 
only tissues treated with Pi calcified regardless of the differentiation state (Figure 4.2A,C) 
suggesting that bone-related gene expression by progenitor cells may be a necessary but 
not a sufficient condition for tissue calcification.  Regarding the SMC markers Acta2 and 
Myh11, Pi treatment had no effect on their expression level in the undifferentiated tissue 
(p>0.05). However, both Acta2 and Myh11 were significantly downregulated in response 
to hyperphosphatemic Pi treatment (p<0.05; Fig 4.2D). The elastin gene expression was 
downregulated by Pi treatment in both differentiated and undifferentiated tissues. The 
downregulation of SMC marker genes was consistent with previous observations that a 
calcified vascular tissue is accompanied by SMC de-differentiation (phenotype switching 
to a less contractile state). The switch to a de-differentiated phenotype is known to lead to 
the loss of contractile SMCs and dysregulation of vascular tone31. The immunostaining 
data presented in Fig 4.2E were consistent with the gene expression trend suggesting 
protein translation. These data collectively demonstrated the benefit of using progenitor (or 
stem) cells to study calcification in an engineered tissue model. On the one hand, 
undifferentiated progenitor cells in the presence of hyperphosphatemic Pi calcified by 
upregulating osteogenic markers; and on the other hand, differentiated SMC cells 
decreased the expression of SMC markers and elastin in the presence of 
hyperphosphatemic Pi and calcified. Gaining such information is one of the advantages of 
using engineered vascular tissues as isolated systems to systematically evaluate 
physiological processes that might not be feasible to do in vivo.  The results of Figure 
4.2A, while demonstrating that hyperphosphatemic Pi induces calcification, it does not 
prove whether this is due to passive precipitation in the tissue space or a cell-mediated 
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process. Thus, acellular scaffolds (cell-free fibrin gel tubes) were tested for potential 
calcification. As presented in Figure 4.3A, the cell-free tubes did not calcify, whereas the 
corresponding engineered vascular tissues were calcified, demonstrating that the process 
is mediated by cells (Figure 4.3A bottom images and Figure 4.3B top images). 
4.4.3 Protective role of vitamin K for calcified engineered tissues. 
Recent evidence suggests a protective role of vitamin K against calcification by exhibiting 
anti-inflammatory effects and by activating matrix Gla protein (MGP) which is considered 
a potent calcification inhibitor32. Based on this information, the potential protective effect 
of vitamin K treatment in both undifferentiated and differentiated tissues exposed to 
hyperphosphatemic Pi was investigated. Both undifferentiated and differentiated tissues 
were treated with 2.5 mM Pi for one week followed by another week with a combination 
of 2.5 mM Pi and 20 µg/mL vitamin K. Untreated tissues, 2.5 mM Pi treated tissues, and 
tissues treated with 20 µg/mL vitamin K served as controls. The tissues were then cryo-
sectioned and stained with Alizarin Red S. The results showed that while Pi-treated tissues 
(both differentiated and undifferentiated) had marked calcium deposition, the level of 




Figure 4.3. Cell-mediated calcification in differentiated and undifferentiated engineered 
vascular tissues and the protective role of vitamin K. (A) cell-free (acellular) fibrin gels 
were incubated with or without 2.5 mM of inorganic phosphate (Pi) for 7 days and stained 
using Alizarin Red S to rule out passive precipitation. In contrast, cell-based engineered 
tissues from undifferentiated and differentiated cells actively calcified over two weeks, as 
shown by the intense Alizarin Red S staining. (B)  Alizarin Red S for calcium deposits and 
immunofluorescence staining for osteogenic marker osteopontin (OPN) in differentiated 
and undifferentiated tissues are shown for the one-week calcification period.  Positive 
Alizarin Red S staining was accompanied by the expression of OPN (top four images). 
Following another week in the presence of 2.5mM Pi and 20 µg/mL vitamin K, Alizarin 
Red S staining intensity was diminished along with OPN due to the protective role of 
vitamin K (bottom four images). Scale bar = 50 µm. 
 
Furthermore, OPN immunofluorescence staining showed a similar trend (Figure 4.3B), 
corroborating the Alizarin Red S staining data. Comparing the one week with two weeks 
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of Pi-treatment histological images (Figure 4.3B top images vs. Figure 4.3A bottom 
images), it is clear that calcification increased, as shown by the intense staining at two 
weeks. Remarkably, the presence of vitamin K not only protected the tissue against further 
calcification but also considerably abrogated it. The effect of vitamin K treatment on gene 
and protein expression in these tissues was also examined. Figure 4.4A shows the level of 
osteogenic and SMC contractile marker expressions from the undifferentiated tissues 
treated with vitamin K and Pi. While Spp1 was downregulated in response to vitamin K 





Figure 4. 4. The effect of vitamin K on undifferentiated and differentiated tissues gene and 
protein expression. (A) Osteogenic and contractile markers gene expression in 
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undifferentiated tissues treated with Pi, Vitamin K, or a combination. (B)  Osteogenic and 
contractile markers gene expression in differentiated tissues treated with Pi, Vitamin K or 
a combination.(C)  Immunofluorescence microscopy of contractile markers in 
undifferentiated and differentiated tissues treated with 2.5 mM Pi and in the presence of 
vitamin K. Scale bare = 50 µm. For Figs. A and B, data are means ± SD (n=3) and one-
way ANOVA and Tukey’s multiple comparison tests were used for statistical analysis. 
Different letters indicate the significance at p<0.05, while similar letters indicate no 
significance (p>0.05). 
 
Gene expression of differentiated tissues treated with vitamin K and Pi is shown in Figure 
4.4B. Osteogenic markers did not change after treating the calcified tissues with Vitamin 
K (Figure 4B1-B3); however, Vitamin K treatment was able to rescue the gene expression 
of contractile markers Acta2 and Myh11 (Figure 4B4 and B5). Similar results were 
observed from immunostaining (Figure 4.4C).   
4.4.4 The effect of exogenous partially-soluble elastin on the calcification of 
engineered vascular tissues. 
The extracellular matrix (ECM) is an integral component of tissues that not only acts as a 
structural support of its cellular components but also affects cellular processes such as 
proliferation, differentiation, survival, and apoptosis. Elastin is a major protein that is found 
in the ECM of arteries and studies have implicated elastin degradation in causing vascular 
calcification33. Thus, the effect of elastin and inorganic phosphate on the expression of 
osteogenic and SMC markers in these engineered vascular tissues was investigated. To that 
end, partially-soluble elastin was used as a surrogate to degraded elastin and its effect on 
calcification in both undifferentiated and differentiated engineered tissues was tested. 




Figure 4.5. The effect of partially-soluble elastin (simulating degraded elastin) on 
calcification and de-differentiation gene expression in engineered vascular tissues. (A) 
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Contractile and osteogenic gene expression in elastin-containing non-differentiated tissues 
with or without 2.5 mM inorganic phosphate treatment. Undifferentiated tissues that do not 
contain elastin were used as controls. (B)  Contractile and osteogenic gene expression in 
elastin-containing differentiated tissues with or without 2.5 mM inorganic phosphate 
treatment. Differentiated tissues that do not contain elastin were used as controls. Data are 
means ± SD (n=3) and one-way ANOVA and Tukey’s multiple comparison tests were used 
for statistical analysis. Different letters indicate the significance at p<0.05, while similar 
letters indicate no significance (p>0.05). 
 
In the undifferentiated tissues, the presence of elastin alone did not affect the expression of 
any of the tested genes with the exception of Myh11 which was significantly downregulated 
(Figure 4.5A; p<0.05).  The addition of Pi with or without elastin did not change the 
expression of Spp1 or Runx2; however, Alp1 and Acta2 expression increased in the 
elastin+Pi group. Conversely, the expression of Myh11 was downregulated in the 
elastin+Pi group (Figure 4.5A). While Alp1 and Myh11 behavior was consistent with a 
calcifying tissue, the overexpression of Acta2 was not expected as SMC contractile markers 
were predicted to be downregulated (which is the case with Myh11).  
Differentiated tissues exhibited a different gene expression profile than undifferentiated 
tissues (Figure 4.5B). Unlike the undifferentiated tissues, partially-soluble elastin led to an 
increase in the expression of Alp1, Spp1, Runx2, and Acta2; however, Myh11 expression 
decreased. On the other hand, Pi treatment of tissues did not change the levels of Alpl or 
Spp1 with respect to the control; but, the expression levels of Runx2, Acta2 and Myh11 
decreased. Interestingly, the effect of combined elastin + Pi treatment on the differentiated 
tissues followed a similar trend as the undifferentiated tissues. The data seems to suggest 
that while elastin on its own might not affect progenitor cells, it had an effect on the 
differentiated cells by inducing them to express higher levels of osteogenic markers while 
downregulating the late SMC differentiation marker (Myh11) which indicates SMC de-
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differentiation. In addition to partially-soluble elastin, similar experiments using 
tropoelastin were conducted, and the same trend was observed for both differentiated and 
undifferentiated engineered tissues (data not shown).  
4.5 Discussion  
In this study (schematically summarized in Figure 4.6), embryonic multipotent 
mesenchymal progenitor cells (10T1/2 cells) were used to engineer vascular tissue models 
and the role of their differentiation state on calcification and associated gene and protein 
expression was studied. 
 
Figure 4.6. Schematic representation of the calcification process in differentiated and 
undifferentiated engineered vascular tissues. Progenitor cells can either be used to fabricate 
undifferentiated tissues that calcified in the presence of Pi. Alternatively, they can be 
differentiated to SMC to fabricate tissues that can calcify in the presence of Pi.  Treating 
differentiated tissues with hyperphosphatemic Pi concentration leads to the de-
differentiation of SMC by downregulating SMC-markers. The addition of vitamin K 
restores SMC-marker expression signifying a protective and rescuing role. On the other 
hand, the presence of partially-soluble elastin in the differentiated tissues led to the 
downregulation of late SMC-markers and upregulation of osteogenic markers. 
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Additionally, the treatment of undifferentiated tissues with a high concentration of Pi 
directly leads to overexpression of osteogenic markers without affecting SMC genes.  
 
Furthermore, the role of vitamin K as a protective agent of calcification was shown. Finally, 
the addition of partially-soluble elastin could lead to the de-differentiation of SMC and 
upregulation of osteogenic markers.  10T1/2 cells have emerged as a model cell in vascular 
tissue engineering and could be differentiated to SMC by expressing smooth muscle α-
actin (ACTA2), smooth muscle myosin heavy chain (MYH11) and smoothelin (SMTN) 
prior to their incorporation to the fibrin gel.  While both smooth muscle α-actin and smooth 
muscle myosin heavy chain are also expressed in myofibroblasts derived from progenitor 
cells, including 10T1/2 34, 35, smoothelin is the only definitive marker for a smooth muscle 
cell differentiation36, 37 (Figure 4.1D and Figure 4.2E). Both 2D (pre-differentiation) and 
3D (in situ) differentiation strategies have been evaluated but pre-differentiation was found 
to be more effective (Figure 4.1C). The lack of in situ differentiation was attributed to 
diffusion, where the compacted gel provided the barrier for TGFβ1 transport to induce its 
action on 10T1/2 cells. Diffusion gradients of signaling factors having typical diffusion 
coefficients in the order of 10-8 to 10-11 m2/s are known to slow stem cell differentiation in 
3D 38, 39.  
In this study, 2.5mM Pi was specified as hyperphosphatemic concentration compared to 
1.4mM which is considered as physiologic40. In response to hyperphosphatemic 
concentration, tissues engineered from undifferentiated and differentiated cells calcified, 
and such a comparative study is the first to be reported, supporting the emerging theory 
that progenitor cells to be involved in vascular calcification41. Although both aortic organ 
culture40 and engineered tissues21 have been reported, neither investigated the role of 
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progenitor cells. Both Alpl and Runx2 were significantly downregulated in response to 7 
days hyperphosphatemic treatment and indicated that degradation of mRNA or protein 
occurred as the vascular calcification developed40.  One of the findings of the current study 
is the protective action of Vitamin K against calcification in engineered vascular tissues. 
In vivo, Vitamin K activates matrix gla protein (MGP) that is a potent binder of 
hydroxyapatite and has been shown to inhibit vascular calcification by scavenging 
hydroxyapatite and calcium oxalate monohydrate crystals42, 43. In clinical observations, 
patients prescribed with the anticoagulant drug warfarin for the prevention and treatment 
of thrombotic and thromboembolic diseases had increased risk of vascular calcification 
since MGP synthesis and activity are blocked by warfarin44. Because Warfarin is a common 
therapy for dialysis patients, vascular calcification is accelerated in chronic kidney disease 
(CKD)45, 46 due to vitamin K antagonism, among other factors. In view of these prior 
studies, the engineered vascular tissues were subjected to vitamin K treatment following 
7-days of calcification to scavenge the deposited calcium phosphate deposits. To this end, 
data in (Figure 4.3) showed that vitamin K blunted further calcification and scavenged the 
deposits likely by activating matrix gla protein, thus demonstrating the ability of 
engineered vascular tissue to recapitulate in vivo studies.     
The engineered tissues did not produce detectable elastin for the studied culture time. 
However, degradation of the extracellular matrix elastin is implicated in vascular 
calcification.  An in vitro study using rat aortic SMCs showed that elastin-derived peptides 
induced osteogenic transformation of cells, and this effect was exacerbated by TGF-β147. 
In an abdominal aorta injury rat model, it is reported that calcification was the result of 
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elastin degradation induced by matrix metalloproteinases48. Furthermore, a recent study 
showed that degradation of elastin using cathepsins resulted in an 8-fold increase in 
elemental phosphate and calcium, and that elastin peptides generated by cathepsin 
degradation led to increased calcification in MOVAS-1 cells and ex vivo mouse aorta 49. In 
view of the above, partially-soluble elastin as a surrogate for degraded elastin was added 
to investigate its role in calcification-related and SMC-related gene expression in both 
undifferentiated and differentiated tissues. While partially-soluble elastin had no clear 
effect on the undifferentiated tissues, the data collectively presented in Figure 4.5B 
demonstrated that differentiated tissues upregulated osteogenic marker genes suggesting a 
calcification process. Furthermore, partially-soluble elastin downregulated smooth muscle 
myosin heavy chain (Myh11) which is a late-stage differentiation marker. This latter point, 
in turn, suggests that SMC may be switching into a synthetic phenotype which is one 
feature of vascular calcification50, 51. Engineered vascular tissues have potential 
applications to model vascular disease and to develop therapeutic targets. While there are 
several reported engineered tissue models to study disease and develop therapeutic 
agents52, engineered vascular tissues for modeling disease are notably absent except for 
two prior studies20, 21.  In the first of these two studies, engineered vascular tissues were 
investigated for lipoprotein infiltration, endothelial layer activation, and monocyte 
adhesion to model atherosclerosis20. In the most recent report21 which is related to this 
study, engineered and decellularized grafts were investigated for mineral aggregates and 
thermal and mechanical properties. Cell-containing engineered vascular tissues were 
excluded from this cited study21 to avoid secretion of mineralization inhibitors. Using 
targeted gene analysis, the present study focused on the role of progenitor and differentiated 
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cells on calcification, the effect of vitamin K to protect and rescue calcified tissues, and the 
role of partially-soluble elastin on calcification – all of which are implicated in clinical 
ectopic calcification studies.   
4.6 Conclusion 
In this study, the potential of engineered vascular tissue models to study calcification was 
reported. While tissues fabricated both from differentiated and progenitor cells can calcify, 
they do so via different gene expression profiles. Undifferentiated tissues upregulated 
osteogenic markers while differentiated tissues downregulated contractile markers under 
hyperphosphatemic conditions. Furthermore, the role of vitamin K in reducing the burden 
of hyperphosphatemic conditions on the engineered tissues was demonstrated suggesting 
a potential adjuvant therapy for patients with vascular calcification. Finally, matrix 
degradation was simulated by using partially-soluble elastin and showed that while elastin 
on its own does not affect osteogenic markers in undifferentiated tissues, it leads to SMC 
de-differentiation and switching to an osteogenic marker expressing tissue. Collectively, 
this study demonstrated these tissue models are promising platforms to study disease and 
potential therapies.  
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Vimentin involvement in Notch signaling and 
neovascularization: an exploratory study 
Overview: Notch is a tightly regulated pathway central to the development and pathology 
of vascular tissues. Recent studies suggested that the intermediate filament vimentin may 
be needed for efficient Notch signaling to occur. In this chapter, the role of vimentin in the 
regulation of the Notch pathway, and the formation of micro-vessels is explored. The data 
reported are exploratory studies. 
5.1 Summary 
The Notch signaling pathway is a conserved pathway that is central in vascular tissue 
development and pathology. Because this pathway controls such important events, it is 
regulated at multiple steps of its cascade, such as post-translational modification of its 
ligand and receptor. Recent studies have suggested regulation of the Notch signaling by a 
pulling force required for the activation of the Notch signaling to take place. In this 
exploratory study, 3D fibrin gels were used as a coculture system of endothelial cells and 
10T1/2 cells to assess whether vimentin is implicated in the regulation of Notch signaling 
and neovascularization. The results show that 10T1/2 cells increase the expression of Hes-
1, Hes-5 and Acta2 during coculture with human coronary artery endothelial cells 
(HCAECs) and that vimentin knock-down using siRNA partially reduced the expression 
under static conditions. On the other hand, while the same trend was observed for Hes-5 
under dynamic conditions, Acta2 was overexpressed, and vimentin knock-down did not 
affect its expression levels. Moreover, the development of newly formed micro-vessels is 
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observed in 3D fibrin gels in the presence of VEGF but could not be formed when vimentin 
expression was knocked down. These results suggest that vimentin plays a secondary role 
in Notch signaling; however, it is essential for neovascularization. 
5.2 Introduction 
Vimentin is a type of intermediate filament protein and is a major component of the 
cytoskeleton. It is widely expressed in many tissues, including the brain, lung, liver, 
gastrointestinal tract, kidneys etc. The vimentin monomer is a 466 amino acid protein and 
has a molecular weight of about 53 kDa (NCBI Reference Sequence: NP_003371.2). 
During assembly, two vimentin polypeptides align and bind, forming a dimer. This step is 
followed by the lateral binding of two dimers to form a tetramer, then eight tetramers bind 
side-by-side, forming the unit length fiber (ULF). The ULFs are the basic building blocks 
of the vimentin intermediate fibers that join end to end1 (Figure 5.1). The assembly of 
vimentin fibers is regulated by phosphorylation of serine residues, which has been shown 
to disassemble the fibrillar structure of vimentin2. Vimentin mainly functions as a structural 
support protein, and earlier studies in vimentin knock-out mice showed that its absence has 
no effect on the survival of mice which showed no obvious abnormalities3. On the other 




Figure 5. 1. Schematic representation of the assembly of vimentin intermediate fibers. 
 
As an example, vimentin plays a role in cell adhesion due to its ability to interact with 
integrin at focal adhesion sites4. Furthermore, vimentin knock-down in alveolar epithelial 
cells using shRNA has been shown to reduce their mobility and consequently affect wound-
closure rates in an in vitro model of lung injury, and ectopic expression of vimentin 
reversed those effects5. Vimentin has also been implicated in other important processes 
such as proliferation6 and differentiation7.  
Interestingly, vimentin has been shown to play a role in regulating signaling pathways, for 
example, by transporting kinases from one part of a cell to another8, or localizing receptors 
to the cell surface9. Of importance to this research, new evidence suggests that the Notch 
signaling pathway requires a force pulling on the ligand-bound receptor to activate the 
signal10, 11. Naturally, the pulling force has to be exerted by the cytoskeleton component, 
and while some studies suggest that the actin fibers are involved11, other studies have 
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pointed to vimentin12, 13. Although the Notch signaling pathway is known to be a prominent 
regulator of vascular development and homeostasis14-16, it is still not a well-understood 
pathway due to its complex regulation and context-dependence. In this exploratory study, 
the role of vimentin in regulating the Notch pathway signaling and its role in 
neovascularization is inspected.  
5.3 Materials and Methods 
5.3.1 Cell culture and tissue fabrication. 
Embryonic multipotent mesenchymal progenitor cells (10T1/2 cells) (ATCC) were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) supplemented with 
5% v/v Fetal Calf Serum (Gibco) and 1% v/v penicillin/streptomycin (Life Technologies). 
Human coronary artery endothelial cells (HCAEC) (Lonza) were maintained in EGMTM-2 
Endothelial Cell Growth Medium-2 BulletKitTM (Lonza). Spent media was exchanged with 
fresh media every three days for 10T1/2 cells and two days for HCAECs. Cells were 
passaged when confluency reached around 80%. For certain experiments, HCAECs were 
treated with 3 ng/mL VEGF, EGF, or bFGF or transfected with vimentin siRNA for 3 days 
prior to coculture with 10T1/2 cells. Some experiments were performed under dynamic 
conditions indicating that the culture plates were incubated on an orbital shaker for 30 
minutes at a speed of 120 rpm for a period of 3 days. 
To fabricate engineered vascular tissues, cultured cells were trypsinized with trypsin-
EDTA 0.05% (Thermofisher) for 2 min and then suspended in DMEM. The cells were 
counted, and the appropriate volume was taken from the cell suspension to give a final cell 
count of 10 million cells/mL of tissue construct. The cells were then centrifuged at 1200 
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rpm for 5 min, the supernatant aspirated and cells resuspended in 150 µL of media. To that, 
3 µL of 2 M CaCl2 and 5 µL of 10 mg/mL ε-aminocaproic acid (ε-ACA) (Sigma-Aldrich), 
and 1 µL of 1U/µL Thrombin (MP Biomedicals) were added. The cell suspension was kept 
on ice until it was mixed with ice-cold 150 µL solutions of 6 mg/mL bovine fibrinogen 
(MP Biomedicals) to give a final concentration of 3 mg/mL fibrinogen per construct. Right 
after mixing the two solutions, the mixture was transferred into a 5 mL round-bottom tube. 
The tubes were then transferred to an incubator at 37 ºC for 1.5 h for crosslinking. A 3 mL 
volume of prewarmed DMEM was then added to the tube. The next day, HCAECs were 
trypsinized using the same procedure, and 1.0 × 104 cells were added to the cultured tissues 
to form an endothelial cell layer, followed by overnight incubation of the tissues to allow 
the endothelial cells to adhere. After that, the tissues were taken out of the tubes and 
cultured in a 50:50 mixture of DMEM: EGM in a culture plate. 
5.3.2 Capillary formation assay in fibrin gel. 
Tissue plugs made of 3 mg/mL fibrinogen and containing a mixture of 10T1/2 (10 million 
cells/mL) and HCAECs or siRNA transfected HCAECs (3 million cells/mL) were made in 
a similar fashion to the tissue preparation protocol above. These plugs were then embedded 
in 1 mg/mL fibrinogen gels containing 3 ng/mL VEGF or a mixture of 3 ng/mL EGF and 
bFGF and incubated for a period of 10 days in the presence or absence of 10 µM FOXC2-
inhibiting Vimentin effector 1 (FiVe1). The HCAECs cells were stained with cell tracker 
red (Life Technologies). 
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5.3.3 Vimentin knock-down with siRNA. 
To knock down the expression of vimentin in HCAECs, siRNA reverse transfection 
protocol was used as described by the manufacturer (Life Technologies) in 24 well plates. 
The following protocol is based on 1 well of a 24 well plate. In brief, the siRNA-
lipofectamine complex was prepared by diluting 6 pmol siRNA in 100 µL of serum and 
antibiotic-free DMEM. To that, 2 µL lipofectamine RNAiMAX (Life Technologies) was 
added and mixed gently and then transferred to a plate well. The mixture was incubated at 
room temperature for 30 minutes. A cell suspension containing 5 × 104 cells /mL was 
prepared, and 0.5 mL of this suspension was added to each well containing the siRNA-
Lipofectamine complex. The plate was incubated for 3 days at 37°C in a CO2 incubator 
before using the cells to allow sufficient time for knock-down. Scrambled siRNA and non-
transfected cells were used as control. 
5.3.4 Immunofluorescence microscopy. 
For 2D studies, cells were seeded in 6-well plates containing a coverslip at a density of 2.5 
× 105 cells per well. After 24 h, cells were either left untreated or were treated with control, 
3 ng/mL bFGF, EGF, VEGF, or treated with 5 µM of FiVe1 for 3 days. After the culture 
period, cells were washed with PBS and fixed with 4% paraformaldehyde for 15 min at 
room temperature (RT).  
Engineered tissues were fixed overnight in 5 mL tubes, washed with PBS 3 times, and 
incubated first in a 15% and then in a 30% solution of sucrose at RT until the tissues sunk 
to the bottom of the tube. The fixed tissues were dabbed using a paper towel to remove the 
excess liquid. After that, the tissues were immersed with OCT compound (Fisher) and 
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transferred into -80 ºC isopropanol. Tissue sections (30 µm thickness) were obtained by 
using a Leica cryostat (Leica) and placed on microscope slides. The slides were washed 
with PBS 3 times for 5 min each to remove the OCT compound. Cells/tissue sections were 
permeabilized with a 0.2% (v/v) Triton x-100 in PBS for 15 min at room temperature and 
then blocked with 5% BSA in PBS-T for 1 h at RT. The blocking solution was aspirated, 
and 100 µL of the appropriate primary antibodies anti-Acta2 and Hes-5 antibodies from 
mouse (Santa Cruz Biotech)) (1:100) in 5% BSA PBS-T were placed on the coverslip and 
covered with a piece of parafilm, and placed in a humid environment at 4º C overnight. 
The cells/tissues were washed 2 × with PBS-T and once with PBS for 5 min each, then 
incubated with the corresponding secondary antibody (Alexa-488 conjugated goat anti-
mouse and Alexa-594 conjugated goat anti-rabbit (Life Technologies)) (1:150)  in 5% BSA 
PBS-T for 1 h at RT in the dark. The coverslips were then washed 2 × with PBS-T and 
once with PBS and incubated with 2 µg/mL DAPI for 5 min, washed with PBS 3 times and 
mounted with anti-fade mounting media. The images were taken by Zeiss Z1 fluorescent 
microscope.  
5.3.5 Endothelial cell separation with PECAM beads. 
For experiments where HCAECs were cocultured with 10T1/2 cells, the two cell types 
were separated using PCAM-conjugated magnetic beads17, 18. Briefly, the cocultured cells 
were washed with HBSS and trypsinized as above. After trypsinization, the cells were 
suspended in DMEM containing 5% FBS then centrifuged at 1200 rpm at room 
temperature for 5 minutes. The supernatant was discarded, and the pellet was resuspended 
in PBS containing 0.1% BSA. PECAM conjugated magnetic beads were used to separate 
the two cell types by using 100:1 bead to HCAECs ratio. After adding the beads to the cell 
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suspension, the tubes were tumbled end-over-end for 30 minutes at 4 ºC. The beads-bound 
cells were then captured using a magnetic rack and the rest of the suspension containing 
the 10T1/2 cells were collected and centrifuged at 1200 rpm at 4 ºC for 5 minutes. The 
10T1/2 cells pellet was collected and washed with ice-cold phosphate-buffered saline 
(PBS) until further use. 
5.3.6 RNA isolation and qPCR.  
Pelleted 10T1/2 cells that were separated from HCAECs were collected by centrifugation 
and 500 µL of Trizol (Life Technologies), and cells were lysed by repeated pipetting. Cells 
were lysed for 10 min at RT, and chloroform was added at a ratio of 1:5 
(chloroform:Trizol), and the samples were vortexed for 15 sec then incubated at RT for 15 
min. Samples were then centrifuged at 4 ºC and 12000×g for 15 min. The organic phase 
was discarded, and the aqueous phase was transferred to another Eppendorf tube. 
Isopropanol was added at a ratio of 1:2 (isopropanol:Trizol) and incubated at RT for 10 
min followed by centrifugation at 12000×g for another 10 min at 4 ºC. The isopropanol 
was then aspirated, and the pellet was resuspended in 75% EtOH at a ratio of 1:2 
(EtOH:Trizol) and centrifuged at 7500×g for 5 min at 4º C. This last step was repeated 
twice to wash excess salts. The pellet was air-dried after the EtOH was removed, dissolved 
in 25 µL of DEPC water, and quantified with nanodrop (Thermo Scientific). 1 µg of total 
RNA was used to synthesize cDNA using M-MLV reverse transcriptase kit (Promega) 
using the supplier’s protocol. For qPCR reactions, 1 µL of the formed cDNA was used in 
10 µL reactions using the SsoAdvanced universal SYBR green supermix (Bio-rad) 
according to the manufacturer’s protocol. The qPCR reactions were carried out in a CFX96 
Real-Time thermal cycler (BioRad), and GAPDH was used as a reference gene. 
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5.3.6 Western blotting. 
The PECAM separated 10T1/2 cells were harvested using centrifugation and lysed in ice-
cold RIPA buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton 
X-100, 0.25% (w/v) sodium deoxycholate and 0.1% (w/v) SDS pH: 7.5) containing 
protease inhibitor cocktail (Roche) and 1 µM Phenylmethanesulfonyl fluoride (PMSF). 
The cells were kept on ice for 15 min to allow for lysis to complete. Lysates were 
centrifuged at 12000 rpm for 15 min. The pellets were discarded, and the supernatants’ 
protein contents were quantified using the Pierce BCA protein assay protocol (Pierce). 
Protein samples were resolved by SDS-PAGE and transferred onto a nitrocellulose 
membrane (Pall life sciences). Blocking the membrane was performed with 5% BSA 
(Sigma-Aldrich) in PBS with 0.1% Tween-20 (PBS-T) and Western blotted with the Acta2 
(1:1000), Hes5 (1:500), and GAPDH (1:1000) primary antibodies (Santa Cruz Biotech) 
diluted in 5% BSA in PBS-T overnight at 4º C. The blots were then washed 2 × with PBS-
T for 5 min each, and 1 × with PBS for 5 min, followed by incubation with goat anti-mouse 
secondary antibody (1:5000) diluted in 5% BSA in PBS-T for 1 h at room temperature. 
Finally, the blots were washed as before and incubated with Supersignal west pico 
chemiluminescence substrate (Pierce) and developed using ChemiDoc XRS+ (BioRad). 
5.3.7 Statistical analysis. 
Data are presented as the means of at least three independent experiments, and the error 
bars represent the standard deviation from the means. Statistical significance was 
calculated using one-way ANOVA. Tukey’s multiple comparison tests were used for post-
hoc statistical analysis. For statistical significance, p-value of <0.05 was used. 
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5.4 Results and Discussion 
5.4.1 Endothelial cell vimentin expression and knock-down. 
The expression of vimentin in endothelial cells is shown in Figure 5.2. Endothelial cells 
were treated with different growth factors bFGF, EGF and VEGF at a 3 ng/mL 
concentration. Inhibition of vimentin filament formation is accomplished by adding 5 µM 
FiVe1 or transfecting endothelial cells with vimentin siRNA. The data showed that the ECs 
cultured in the presence of bFGF grow in close contact with each other similar to the 
control. On the other hand, cells treated with EGF or VEGF were separated, which may 
indicate endothelial-to-mesenchymal (EndMT) transition due to loss of cell-cell contact19. 
This transition is important for the formation of new microvasculature20. Furthermore, ECs 
treated with VEGF and EGF exhibit an elongated shape of the vimentin filament network 
which might also be an indication of the EndMT transition19. The addition of Five1 into 
the culture or transfection of ECs with vimentin siRNA disrupts the vimentin fibers 





Figure 5.2. Fluorescence microscopy of expression of vimentin in HCAEC. HCAEC were 
treated with 3 ng/mL of each bFGF, EGF, and VEGF. Vimentin filament disruption is 
shown by the addition of 5 µM FiVe1 or vimentin knock-down using vimentin siRNA. 
Scale bar = 50 µm. 
 
5.4.2 Role of vimentin in Notch signaling in static and dynamic cultures. 
To assess the role of vimentin in the regulation of the Notch signaling pathway, 10T1/2 
cells were cocultured with endothelial cells (EC), or ECs treated with VEGF, or ECs 
transfected with the vimentin siRNA. Figure 5.3. A shows the expression of three Notch 
target genes, Hes-1; Hes-5 and Acta2, under static conditions.  
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Hes-1 was upregulated in the presence of ECs regardless of EC treatment conditions. Hes-
5 expression was also upregulated in the presence of ECs; however, its expression was 
reduced slightly when vimentin expression was knocked down with siRNA; however, it 
was still higher than control levels. The expression of Acta2 increased in the presence of 
ECs and EC (siRNA) and it was further increased in the VEGF treated ECs. A similar trend 
is observed for the protein expression of Hes-5 and Acta in figure 5.3.C. These results 
show that in static conditions, only the expression of Hes-5 was affected by the knock-





Figure 5.3. Coculture of 10T1/2 and HCAEC in static and dynamic conditions. (A) Hes-
1, Hes-5 and Acta2 gene expression of 10T1/2 cells cocultured with EC, EC treated with 
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VEGF (EC(VEGF)) or EC transfected with vimentin siRNA (EC (siRNA)) in static culture 
conditions. (B) Hes-1, Hes-5, and Acta2 gene expression of 10T1/2 cells cocultured with 
EC, EC(VEGF), and EC (siRNA) in dynamic culture conditions. Letters on top of the 
columns are used for statistical analysis. Different letters indicate a statistically significant 
difference (p<0.05), whereas the same letters indicate no statistical difference (p>0.05). 
(C) Western blot analysis of Acta2 and Hes5 proteins in 10T1/2 cells cocultured with EC, 
EC(VEGF), or EC (siRNA); GAPDH was used as a loading control. 
 
Due to its tight interaction with integrins, vimentin functions as a mechanosensor of 
external forces from outside the cell and relays them to the nucleus allowing the cells to 
respond to such forces21.  Due to this, the static culture conditions were repeated in dynamic 
conditions to assess whether shear forces might have an effect on the role of vimentin in 
regulating the Notch signaling. Under dynamic conditions, the expression of the Hes-1 
gene increased in the presence of EC and is slightly reduced when vimentin is knock-down 
by siRNA (Figure 5.3.B1). A similar pattern is observed for the Hes-5 gene in Figure 
5.3.B2. On the other hand, the expression of Acta2 is upregulated in the presence of EC 
regardless of EC treatment (Figure 5.3.B3). These patterns are reflected at the protein level 
shown by the Western blot (Figure 5.3.C.). These results show that vimentin might play a 
partial role in the Notch signal regulation because there was a slight decrease in the 
expression of Hes-5 when vimentin was knocked down even though the other genes were 
not downregulated. Interestingly, Figure 5.3.C shows that while the expression of Hes-5 
was generally lower in dynamic conditions, a comparison between the control groups of 
static vs. dynamic cultures shows a slight upregulation of the Hes-5 gene. On the other 
hand, the expression of Acta2 appears to be generally upregulated in dynamic conditions. 
This might suggest that shear force alone plays a role in regulating Notch even though it 
might not be through vimentin. The cytoskeleton is a complex network of interconnected 
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microfilaments, intermediate filaments, and microtubules and therefore, there might be a 
redundancy in the role of the cytoskeleton in regulating the Notch signal. Thus, despite the 
vimentin expression was knocked down, other cytoskeletal components might compensate 
to keep vital signaling pathways operational.  
5.4.3 Vimentin filament disruption partially affects Notch signaling. 
The effect of vimentin filament disruption was tested on the Hes-1, Hes-5 and Acta2 gene 
expression levels in 10T1/2 cells cocultured with HCAECs in 2D cultures. Figure 5.4.A 
shows that disruption of vimentin filament networks did not significantly affect the gene 
expression of Hes-1 or Hes-5 Notch target genes even though there was a downward trend 
in expression of both these genes in the FiVe1 treated group. On the other hand, while 
Five1 treatment reduced the gene expression of the Acta2 gene, its expression was still 
higher than the control.  Conversely, Acta2 protein expression levels remained high in 3D 
coculture even in the presence of FiVe1 treated HCAECs, as shown in Figure 5.4.B. This 
data shows that while vimentin filament disruption slightly decreased the gene expression 
of Notch downstream targets, its effect is minimal and does not have a noticeable effect on 
the protein expression level (Figure 5.4.B). This could be due to the redundant role of 
intermediate filaments such as vimentin, where the disruption of one filament network is 




Figure 5.4. Gene and protein expression of 10T1/2 cocultured with HCAEC in 2D and 3D, 
respectively. (A) Hes-1, Hes-5 and Acta2 gene expression in 10T1/2 cells cocultured with 
HCAECs on 2D.  (B) Immunofluorescence microscopy showing expression of Acta2 in 
3D coculture of 10T1/2 and HCAEC in control vs FiVe1 treated tissues. Scale bar = 50 
µm. 
 
5.4.4 Vimentin plays a role in endothelial cell migration and micro-vessel 
formation. 
The ability of endothelial cells to migrate in a 3D environment was tested in response to 
angiogenic growth factors (bFGF + EGF or VEGF). Furthermore, the effect of vimentin 
disruption on this process was tested using a small molecule inhibitor, FiVe1, or gene 




Figure 5.5. Endothelial cell migration and neovascularization in 3D fibrin gel. (A) 
Migration of endothelial cells into low concentration fibrin gel in the presence of bFGF 
and EGF and FiVe1 treated gels. (B) Micro-vessel formation in 3D fibrin gels containing 
VEGF, or HCAECs that were previously transfected with vimentin siRNA. Scale bar = 50 
µm. Dashed white lines indicate tissue outline. The green arrows indicate Acta2 positive 
cells. 
 
The results showed that angiogenic growth factors were able to induce migration of 
endothelial cells out of the 3 mg/mL fibrin gel and into the less concentrated 1 mg/mL 
fibrin gel, which contained the growth factors (Figure 5.5). On the other hand, when 
vimentin filament fiber formation was inhibited, migration was greatly affected. 
Furthermore, while bFGF and EGF combination has been shown to induce growth and 
proliferation in endothelial cells22, VEGF is a notably more potent angiogenic factor since 
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the sprouting micro-vessels are better organized (Figure 5.5.B). Moreover, these micro-
vessels were able to recruit 10T1/2 cells that expressed Acta2 as shown by the green 
staining indicated by the arrows (Figure 5.5.B). Contrarily, siRNA transfected HCAECs 
were not able to migrate out of the 3 mg/mL fibrin; however, they were able to induce 
expression of Acta2 in 10T1/2 cells (Figure 5.5.B), which is in agreement with Figure 
5.4.B. Taken together, these exploratory study results showed that vimentin plays an 
important role in the migration of endothelial cells and recruit 10T1/2 cells to form micro-
vessels.  
5.5 Conclusion 
In this exploratory study, the role of vimentin in the regulation of Notch signaling and 
neovascularization was explored. The results demonstrated that vimentin plays a limited 
role in Notch signaling, as evidenced by a slight reduction of certain Notch signaling targets 
(Hes-5 and Acta2) when vimentin filaments were inhibited. However, vimentin plays a 
much important role in micro-vessel formation, which allows endothelial cells to migrate 
and recruit 10T1/2cells in response to VEGF. While these pilot results shed some light on 
the role of vimentin in the Notch signaling and neovascularization, more research is 
required to fully elucidate the role of this intermediate fiber in the context of vascular 
development. 
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Overview: In this chapter, a general summary of the work done during this research project 
is provided, highlighting important findings. Furthermore, some limitations of this work 
are mentioned, and recommendations are suggested.  
6.1 Summary and conclusions 
In this research project, engineered vascular tissues were used to study the Notch signaling 
pathway and vascular calcification in a physiologically relevant 3D culture system. These 
are novel and useful tools to improve the current understanding of the physiology and 
pathology of the vascular system. Fibrin gel-based vascular tissues were prepared with two 
types of cells to study Notch signaling. Fibrin is known for its biocompatible properties, 
which has been shown to support important cellular processes and has been widely used as 
a biomaterial in vascular tissue engineering1, 2. Physical properties of the fibrin gels were 
tested using rheology, water contact angle, and water mass loss studies. Initially, human 
coronary artery SMCs were selected due to their relevance to vascular tissue engineering; 
however, their extremely limited proliferation potential was an obstacle to obtain enough 
cells to fabricate the tissues. The reason behind the slow proliferation rate is that it heavily 
depends on the age and health of the donor. Therefore, A-10 and 10T1/2 cells were chosen 
as alternatives to the human coronary artery SMCs due to their rapid proliferation potential.  
A-10, 10T1/2 and HCAEC have been coculture in these tissues in various combinations 
and the Notch pathway activation was assessed. In the framework of this study, endothelial 
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cells were used as signal sending cells due to their expression of Jag1 ligand. The A-10 
cells and 10T1/2 cells were used as signal-receiving cells. The former of these two cell 
lines is an embryonic smooth muscle cell from a rat and the latter is a mouse progenitor 
cell line. In this study, the activation of the Notch signaling in these two cell lines were 
evaluated by assessing downstream targets of Notch such as Hes1, Acta23.  
Fibrin gels were found to lose around 70 % of their mass during culture conditions over a 
3-day period. This was attributed to water expulsion rather than degradation since the 
plasmin inhibitor ACA was present throughout the culture period. SEM images also 
confirmed that fibrin fibers did not seem to be degraded after 3 days of culture. Moreover, 
it was expected that the presence of cells might affect the contraction of these gels; 
however, the presence of cells up to a concentration of 1 million cells had no effect, and 
the concentration of fibrinogen had a bigger effect on contraction. Additionally, cell studies 
showed that while 10T1/2 cells were shown to be responsive to the activation of the Notch 
signaling by endothelial cells, A-10 cells failed to do so likely due to cis-inhibition. It is 
well established that Notch signaling is extremely context-dependent despite its simple 
transduction mechanism4. Furthermore, Notch is implicated in key processes during 
vascular development since disruption of this pathway has been shown to cause 
underdeveloped vasculature as well as the progression of certain diseases5-8. Since this 
pathway was activated in 10T1/2 cells, which are considered multipotent cells that are not 
terminally differentiated, it can be concluded that the Notch signaling plays an active role 
in cell commitment. On the other hand, because Notch signaling was not activated in A-10 
cells, which are committed but immature SMCs, it might be possible that other signaling 
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pathways that crosstalk with Notch must be regulated to drive differentiation of these 
SMCs into a contractile phenotype. Indeed, other pathways are involved in the 
development and maintenance of the vasculature do cross-talk with the Notch pathway9.  
The results in chapter 3 demonstrate the context-dependence of the Notch signaling 
pathway and introduce fibrin-based tissues as a relevant tool that can be used to further 
understand this important pathway and, consequently, the development of better-
engineered tissues. 
Vascular calcification is a common occurrence in the elderly population and in patients 
suffering from chronic kidney disease. While much of  the current understanding of 
vascular calcification comes from studies in 2D cell culture and animal models, EVTs can 
be a powerful tool in the researchers' repertoire that can accelerate the understanding of 
this disease and aid in devising strategies to reduce its impact on the affected populations. 
In chapter 4, 10T1/2 cells were used in both their undifferentiated and differentiated forms 
to shed light on the progression of calcification in an isolated culture system. There is a 
debate in the literature about the source of cells that contribute to the vascular calcification. 
Some research points towards SMCs10 while others attribute it to circulating stem cells11, 
12. Results in chapter 4 showed that tissues made from both undifferentiated and 
differentiated 10T1/2 cells calcified, albeit via different mechanisms. Undifferentiated 
10T1/2 cells upregulated certain osteogenic markers, while differentiated cells down-
regulated SMCs markers in response to the calcification stimulus. However, both tissues 
expressed osteopontin. This commonality between the two types of tissues might be a 
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coping mechanism of cells to reduce the concentration of cytoplasmic calcium by 
sequestering it using osteopontin and then exporting it outside the cell. 
Furthermore, elastin degradation has been linked to vascular calcification13. In the elderly 
population, elastin degradation is a natural aging process and might contribute to vascular 
calcification. The degradation of elastin was simulated by incorporating a partially soluble 
form of elastin into the tissues. Interestingly, the two tissue types responded differently to 
this stimulus on the genetic level. While undifferentiated tissues were largely unaffected, 
differentiated tissues downregulated late SMC markers and upregulated osteogenic 
markers in the presence of elastin. Moreover, the engineered tissues were used to test the 
effectiveness of vitamin K in reducing the burden of calcification. Vitamin K is a lipid-
soluble molecule that plays a role in coagulation; however, it has also been shown to help 
reduce calcification14. Vitamin K activates the calcium-binding protein matrix gla protein, 
by carboxylation leading to attenuated calcification. Therefore, the calcified engineered 
tissues were used to test the efficacy of vitamin K to diminish the extent of calcification. 
Both types of tissue responded to vitamin K treatment, which reduced the level of 
calcification and downregulated osteopontin protein expression. Data collectively 
presented in Chapter 4 revealed the potential of engineered tissues to study and model 
diseases and test drugs. This strategy can narrow the focus of research work before moving 
into animal models to study the problem on a systemic level. 
Chapter 5 is an extension of chapter 3. Notch signaling has been shown to require a pulling 
force to be activated. While this concept is still debatable, it might also be context 
dependent. Unsurprisingly, the involvement of a mechanical force suggests that the 
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cytoskeletal components are at play. While some studies showed that the actin-myosin 
might be responsible for that force15, other studies suspect vimentin16, 17. The preliminary 
results in chapter 5 showed that while inhibition of vimentin fiber formation may partially 
reduce the strength of the Notch signaling, it does not completely inhibit it. This may 
indicate that the cytoskeleton as a whole, including the microfilament, intermediate 
filaments, and microtubules, contribute to a certain extent in generating that force. 
Moreover, the results show that vimentin plays a key role in forming new vessels since 
knocking its expression down or inhibiting its polymerization will prevent 
neovascularization. However, more research is needed to explore the role of intermediate 
filaments in Notch signal regulation. 
6.2 Contribution to the research field 
In this thesis, engineered vascular tissues fabricated from fibrin hydrogels were used in a 
novel approach to study the Notch pathway. Notch signaling is a central pathway for 
vascular development and homeostasis. While this pathway was discovered over a century 
ago, there is still much to uncover due to its context-dependence. Much of the knowledge 
we have of Notch signaling comes from 2D cell culture and animal models; therefore, 
utilizing fibrin-based tissues sheds a different light on this pathway. One of the first steps 
of this research was to characterize the properties of this cell culture system. While 
previous studies have shown that fibrin gels compact18, kinetic changes in the mass of these 
gels were shown here. Furthermore, these results also show acellular fibrin gel compaction.  
On the signaling front, the two cell lines used in these studies responded oppositely, which 
highlights context-dependence. Differentiated but immature SMCs cell line A-10 failed to 
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activate Notch signaling, while multipotent 10T1/2 cells upregulated Hes- and SMC 
markers in response to coculture with endothelial cells. This upregulation was abolished 
when treated with DAPT, signifying that the upregulation of SMC markers was via the 
Notch pathway. The dichotomy in the response of these two cell lines suggests that Notch 
signaling is not as simple as cell-cell interaction, but other factors affect the activation of 
this pathway. Furthermore, preliminary results on the role of vimentin in Notch signaling 
was also explored. These results indicate that the cytoskeleton is not merely for structural 
support, but different cytoskeletal components might play a complementary part to control 
vital processes such as signaling mechanisms.  
Additionally, the use of engineered vascular tissues to study the effect of calcification on 
progenitor and differentiated cells was the first of its kind. The source of calcifying cells in 
the vasculature has never been studied in engineered tissues. In this work, 10T1/2 were 
used as model cells because it serves the role of both progenitor and differentiated SMCs. 
There is debate as to what are the source of calcifying cells in the literature. Results in this 
work have shown that both progenitor and differentiated cells are capable of calcifying in 
response to high concentrations of inorganic phosphates. However, the two phenotypes 
calcify through different processes, which were ameliorated with the treatment of vitamin 
K. Moreover, elastin degradation was simulated by adding elastin to the engineered tissues 
and also showed different gene expression profiles between the two types of tissues. This 
work underscores the practicality of engineered tissues to study vascular calcification and 




Even though fibrin is a promising hydrogel commonly used in engineered vascular tissues, 
it is not a protein found in the ECM of vascular tissues. Fibrin gel was chosen as a 
biomaterial for its well-established biocompatibility and the ability to incorporate cells in 
the process of fabrication, allowing for high cell density tissues. However, it is only meant 
as a temporary scaffold that would be remodeled and replaced by ECM proteins secreted 
by the resident cells. Collagen and elastin are the main proteins found in the ECM of 
vascular tissues. While elastin is challenging to incorporate into the hydrogel due to low 
solubility, collagen would be a good alternative for fibrin, or maybe a mixture of fibrin and 
collagen could be used for further studies. 
Another limitation of this research is the use of non-human A-10 and 10T1/2 cells which 
are sourced from rats and mice. The use of these cells was due to the slow proliferation rate 
of human smooth muscle cell types, which often depends on the donor's age and health 
status. Nevertheless, the use of A-10 and 10T1/2 cells has provided valuable information 
that can be used to design future studies using human cells. 
Vascular tissues are continuously exposed to pulsatile and shear forces. The work in this 
thesis was done mostly in static conditions, yet another limitation that can be addressed to 
reflect a more realistic environment. 
6.4 Recommendations 
This research project has laid the foundation for the use of engineered vascular tissues to 
study cell signaling and disease. However, it also warrants further research to advance the 
understanding of vascular development and disease which will ultimately lead to a better 
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engineered tissues. For that purpose, the following are some suggestions that can build on 
this work: 
1- Incorporation of relevant ECM proteins: Collagen can be incorporated or produced 
by cells by the addition of ascorbic acid into the media. Collagen is a major component 
of the vasculature and might provide a more relevant microenvironment for cells.  
2- Mechanical stimulation: Pulsatile and shear forces are known to be important for the 
development of tissues and the progression of diseases. Furthermore, these forces might 
play a role in the activation of signaling pathways such as Notch signaling. Therefore, 
it would be beneficial to expose those tissues to dynamic forces and study the effect 
they have on either the signaling or progression of calcification. 
3- Human sourced cells: Ultimately, these studies are geared towards an understanding 
of human physiology and pathology. Therefore, it would be useful to utilize human-
sourced cells that can give more relevant results. Cells like mesenchymal stem cells or 
induce pluripotent stem cells are good candidates due to their relatively high 
proliferation rate prior to differentiation.  
6.5 References  
1. Gui, L.; Boyle, M. J.; Kamin, Y. M.; Huang, A. H.; Starcher, B. C.; Miller, C. A.; 
Vishnevetsky, M. J.; Niklason, L. E., Construction of tissue-engineered small-diameter 
vascular grafts in fibrin scaffolds in 30 days. Tissue Eng Part A 2014, 20, (9-10), 1499-
507. 
2. Syedain, Z. H.; Meier, L. A.; Bjork, J. W.; Lee, A.; Tranquillo, R. T., Implantable 
arterial grafts from human fibroblasts and fibrin using a multi-graft pulsed flow-stretch 
bioreactor with noninvasive strength monitoring. Biomaterials 2011, 32, (3), 714-22. 
3. Dayekh, K.; Mequanint, K., Comparative Studies of Fibrin-Based Engineered 
Vascular Tissues and Notch Signaling from Progenitor Cells. ACS Biomater. Sci. Eng. 
2020, 6, (5), 2696-2706. 
152 
 
4. Schwanbeck, R.; Martini, S.; Bernoth, K.; Just, U., The Notch signaling pathway: 
molecular basis of cell context dependency. Eur J Cell Biol. 2011, 90, (6-7), 572-581. 
5. Gallardo, A.; Latapiat, V.; Rivera, A.; Fonseca, B.; Roldan, A.; Sandoval, P.; 
Sanchez, C.; Matamala, J. M., NOTCH3 Gene Mutation in a Chilean Cerebral Autosomal 
Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Family. J 
Stroke Cerebrovasc Dis 2020, 29, (2), 104530. 
6. Joutel, A.; Andreux, F.; Gaulis, S.; Domenga, V.; Cecillon, M.; Battail, N.; J., The 
ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of 
CADASIL patients. J Clin Invest. 2000, 105, (5), 597-605. 
7. Rostama, B.; Peterson, S. M.; Vary, C. P.; Liaw, L., Notch signal integration in the 
vasculature during remodeling. Vascul Pharmacol 2014, 63, (2), 97-104. 
8. Santio, N. M.; Landor, S. K.-J.; Vahtera, L.; Ylä-Pelto, J.; Paloniemi, E.; Imanishi, 
S. Y.; Corthals, G.; Varjosalo, M.; Manoharan, G. B.; Uri, A.; Lendahl, U.; Sahlgren, C.; 
Koskinen, P. J., Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling 
in breast and prostate cancer cells. Oncotarget 2016, 7, (28), 43220-43238. 
9. Blokzijl, A.; Dahlqvist, C.; Reissmann, E.; Falk, A.; Moliner, A.; Lendahl, U.; 
Ibanez, C. F., Cross-talk between the Notch and TGF-beta signaling pathways mediated by 
interaction of the Notch intracellular domain with Smad3. J Cell Biol 2003, 163, (4), 723-
8. 
10. Kapustin, A. N.; Chatrou, M. L. L.; Drozdov, I.; Zheng, Y.; Davidson, S. M.; 
Soong, D.; Furmanik, M.; Sanchis, P.; Rosales, R. T. M. D.; Alvarez-Hernandez, D.; 
Shroff, R.; Yin, X.; Muller, K.; Skepper, J. N.; Mayr, M.; Reutelingsperger, C. P.; Chester, 
A.; Bertazzo, S.; Schurgers, L. J.; Shanahan, C. M., Vascular Smooth Muscle Cell 
Calcification Is Mediated by Regulated Exosome Secretion. Circ Res. 2015, 116(8):1312-
23. 
11. Chen, J. H.; Yip, C. Y.; Sone, E. D.; Simmons, C. A., Identification and 
characterization of aortic valve mesenchymal progenitor cells with robust osteogenic 
calcification potential. Am J Pathol 2009, 174, (3), 1109-19. 
12. Weishan, W.;  Changjun, L.;  Lijuan, P.;  Chenhui, S.;  G.Fengjing;  Anmin, C.;  
Xu, C.; Mei, W., Mesenchymal Stem Cells Recruited by Active TGFβ Contribute to 
Osteogenic Vascular Calcification. Stem Cells Dev. 2014, 23 (12), 1392-404 
13. Andrault, P. M.; Panwar, P.; Mackenzie, N. C. W.; Bromme, D., Elastolytic activity 
of cysteine cathepsins K, S, and V promotes vascular calcification. Sci Rep 2019, 9, (1), 
9682. 
14. Shioi, A.; Morioka, T.; Shoji, T.; Emoto, M., The Inhibitory Roles of Vitamin K in 
Progression of Vascular Calcification. Nutrients 2020, 12, (2), 583. 
153 
 
15. Hunter, G. L.; He, L.; Perrimon, N.; Charras, G.; Giniger, E.; Baum, B., A role for 
actomyosin contractility in Notch signaling. BMC Biol. 2019, 17, (1), 12. 
16. Engeland, N. C. A. v.; Rodriguez, F. S.; Rivero-Müller, A.; Ristori, T.; Duran, C. 
L.; Stassen, O. M. J. A.; Antfolk, D.; Driessen, R. C. H.; Ruohonen, S.; Ruohonen, S. T.; 
Nuutinen, S.; Savontaus, E.; Loerakker, S.; Bayless, K. J.; Sjöqvist, M.; Bouten, C. V. C.; 
Eriksson, J. E.; Sahlgren, C. M., Vimentin regulates Notch signaling strength and arterial 
remodeling in response to hemodynamic stress. Sci Rep. 2019, 9, (1), 12415. 
17. Antfolk, D.; Sjöqvist, M.; Cheng, F.; Isoniemi, K.; Duran, C. L.; Rivero-Muller, 
A.; Antila, C.; Niemi, R.; Landor, S.; Bouten, C. V. C.; Bayless, K. J.; Eriksson, J. E.; 
Sahlgren, C. M., Selective regulation of Notch ligands during angiogenesis is mediated by 
vimentin.  Proc Natl Acad Sci U S A. 2017, 114, (23), E4574-E4581. 
18. Yao, L.; Swartz, D. D.; Gugino, S. F.; Russell, J. A.; Andreadis, S. T., Fibrin-based 
tissue-engineered blood vessels: differential effects of biomaterial and culture parameters 
















Khalil Dayekh  
Education PhD (Chemical & Biochemical Engineering) 
University of Western Ontario, 2021 
Thesis title: Fibrin-Based Engineered Vascular Tissues as Platforms 
for Cellular Studies and Disease Modeling 
 
MSc (Biochemistry)  
 
University of Ottawa, 2013 
 





University of Ottawa, 2010 
Experience 
 
Teaching Assistant, University of Western Ontario 
• Chemical Plant Design and Safety (January 2018 – April 2018) 
• Aspen Hysys Simulation, (September 2017 - December 2017) 
• Chemical Process Safety, (May 2017 – June 2017) 
• Design and Analysis Principles (January 2017 – April 2017) 
• Bioprocess and Bioengineering (September 2016 – December 
2016) 
• Chemical Process and Plant Design, (September 2015 - April 
2016) 
• Engineering Communications (January 2015 - April 2015) 
 
Laboratory Technician, Ottawa hospital research institute 
(August 2013 – July 2014) 
157 
 
Volunteering • Volunteered in the Let’s Talk Science program at the University 
of Western Ontario (2015 – 2017). 
• Volunteered as a member of the student Health Plan Committee, 
University of Western Ontario (2015). 
• Volunteered in the Let’s Talk Science program at the University 
of Ottawa (2012-2013) 
• Cooperative education program volunteer, Hillcrest high school 
and Ottawa Hospital Research Institute (2012). 
Awards • Awarded the OGS at the University of Western Ontario (2015-
2016) & (2016-2017) 
• Awarded the Dean’s scholarship during master’s studies (2012). 
• Awarded the Cooperative Education Certificate of Appreciation 
for active participation and support of the cooperative education 
program (2012). 





• Laurie Ma, Nima Niknejad, Ivan Gorn-Hondermann, Khalil 
Dayekh, Jim Dimitroulakos. Lovastatin induces multiple stress 
pathways including LKB1/AMPK activation that regulate its 
cytotoxic effects in squamous cell carcinoma cells.  PLoS One. 
2012;7(9):e46055. doi: 10.1371/journal.pone.0046055. Epub 
2012 Sep 28. PMID: 23029387; PMCID: PMC3460930. 
• Khalil Dayekh, Stephanie Johnson-Obaseki, Martin Corsten, 
Patrick J. Villeneuve, Harmanjatinder S. Sekhon, Johanne I. 
Weberpals and Jim Dimitroulakos. Monensin Inhibits Epidermal 
Growth Factor Receptor Trafficking and Activation: Synergistic 
Cytotoxicity in Combination with EGFR Inhibitors.  Mol Cancer 
Ther. 2014;13(11):2559-71. doi: 10.1158/1535-7163.MCT-13-
1086. Epub 2014 Sep 4. PMID: 25189541. 
158 
 
• Khalil Dayekh and Kibret Mequanint. Convergence of Notch 
Signaling Pathway and the Elastin Receptor (ERC) in Fibrin-based 
Vascular Tissue Constructs. European Chapter Meeting of the 
Tissue Engineering and Regenerative Medicine International 
Society June 26-30 2017, Davos, Switzerland. 
• Carley Ort, Khalil Dayekh, Malcolm Xing, and Kibret 
Mequanint. Emerging Strategies for Stem Cell Lineage 
Commitment in Tissue Engineering and Regenerative Medicine. 
ACS Biomater Sci Eng. 2018;4(11):3644-3657. doi: 
10.1021/acsbiomaterials.8b00532. Epub 2018 Aug 20. PMID: 
33429592. 
• Khalil Dayekh, and Kibret Mequanint. Engineered Vascular 
Tissues to Model and Study Disease. 35th Annual Meeting of the 
Canadian Biomaterials Society May 21-24 2019, Quebec City, 
Canada. 
• Khalil Dayekh, and Kibret Mequanint. Comparative Studies of 
Fibrin-Based Engineered Vascular Tissues and Notch Signaling 
from Progenitor Cells. ACS Biomater Sci Eng. 2020;6(5):2696-
2706. doi: 10.1021/acsbiomaterials.0c00255. Epub 2020 Mar 30. 
PMID: 33463301. 
• Khalil Dayekh, and Kibret Mequanint. The Effects of Progenitor 
and Differentiated Cells on Ectopic Calcification of Engineered 
Vascular Tissues. Acta Biomater. Acta Biomater. 2020;115:288-
298. doi: 10.1016/j.actbio.2020.08.019. Epub 2020 Aug 25. 
PMID: 32853805. 
 
